



US009119803B2

(12) **United States Patent**
Yan et al.

(10) **Patent No.:** **US 9,119,803 B2**
(45) **Date of Patent:** **Sep. 1, 2015**

(54) **CARIOUS TOOTH VACCINE AND PREPARATION METHOD**

(75) Inventors: **Huimin Yan**, Wuhan (CN); **Wei Shi**, Wuhan (CN); **Ying Sun**, Wuhan (CN); **Jingyi Yang**, Wuhan (CN)

(73) Assignee: **Wuhan Institute of Virology, Chinese Academy of Sciences**, Wuhan (CN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/234,145**

(22) PCT Filed: **Dec. 29, 2011**

(86) PCT No.: **PCT/CN2011/084876**
§ 371 (c)(1),
(2), (4) Date: **Jan. 21, 2014**

(87) PCT Pub. No.: **WO2013/091260**
PCT Pub. Date: **Jun. 27, 2013**

(65) **Prior Publication Data**
US 2014/0161836 A1 Jun. 12, 2014

(30) **Foreign Application Priority Data**
Dec. 23, 2011 (CN) 2011 1 0438088

(51) **Int. Cl.**
A61K 39/09 (2006.01)
A61K 39/02 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 39/092** (2013.01); **A61K 39/09** (2013.01); **A61K 2039/543** (2013.01); **A61K 2039/55594** (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/00; A61K 38/16; A61K 39/00; A61K 39/02; A61K 39/09
USPC 424/9.1, 9.2, 184.1, 185.1, 234.1, 244.1
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

CN 101411872 * 4/2009

OTHER PUBLICATIONS

Lehner et al., Immunization with Purified Protein Antigens from *Streptococcus mutans* Against Dental Caries in Rhesus Monkeys. *Infection and Immunity* 34, 407-415 (1981).

Saito et al. Protective Immunity to *Streptococcus mutans* Induced by Nasal Vaccination with Surface Protein Antigen and Mutant Cholera Toxin Adjuvant.

* cited by examiner

Primary Examiner — Rodney P Swartz

(74) *Attorney, Agent, or Firm* — George Dacai Liu

(57) **ABSTRACT**

The present invention provides a vaccine composition for dental caries caused by *S. mutans* infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of *S. mutans* and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by *S. mutans* by administering to a subject the vaccine composition.

9 Claims, 15 Drawing Sheets




FIG 1






FIG 2




(a)



(b)

FIG 3



(c)

FIG 3 (cont'd)






FIG 4



(A)

Keys score of caries in different parts of molar teeth



(B)

FIG 5




FIG 6






FIG 7



(A)



(B)

FIG 8




FIG 9





FIG 10






FIG 10 (cont'd)




(A)



(B)

FIG 11



(C)

FIG 11 (cont'd)




FIG 12

1

CARIOUS TOOTH VACCINE AND PREPARATION METHOD

FIELD OF THE INVENTION

The present invention generally relates to the technologies of vaccines, and more particularly to a dental caries vaccine and further to methods for preparing the vaccine.

BACKGROUND OF THE INVENTION

Streptococcus mutans (*S. mutans*) has been implicated as the primary etiological bacteria causing dental caries in human. *S. mutans* expresses a surface protein, designated as antigen I/II, B, P1, or PAc. PAc is involved in the initial adherence of *S. mutans* to tooth surface and the later aggregation of *S. mutans* on the tooth surface; thus PAc is considered a crucial virulence factor, contributing to the pathogenesis of dental caries. Due to its importance in the cariogenicity of *S. mutans*, PAc is recognized as a target for development of anti-caries vaccines.

Streptococcus mutans (*S. mutans*) has been implicated as the primary etiological bacteria causing dental caries in human. *S. mutans* expresses a surface protein, designated as antigen I/II, B, P1, or PAc. PAc is involved in the initial adherence of *S. mutans* to tooth surface and the later aggregation of *S. mutans* on the tooth surface; thus PAc is considered a crucial virulence factor, contributing to the pathogenesis of dental caries. Due to its importance in the cariogenicity of *S. mutans*, PAc is recognized as a target for development of anti-caries vaccines.

In one early study, Lehner et al. (Immunization with Purified Protein Antigens from *Streptococcus mutans* Against Dental Caries in Rhesus Monkeys. *Infection and Immunity* 34, 407-415 (1981)) had purified protein antigens I, I/II, II, and III from bacterial culture directly. The purified antigens were intramuscularly administered with adjuvant (Freund incomplete adjuvant or aluminum hydroxide). Antigens I, I/II and, to a lesser extent, antigen II induced significant reductions in dental caries, but there was no reduction in caries with antigen III. Protection against caries was associated predominantly with serum and gingival crevicular fluid IgG antibodies. Under the immunization schemes used in this study, serum IgA antibodies showed titers of between \log_2 0.7 and 2.8. However, the purities of the antigens used in the experiments were in question. In addition, the claimed effectiveness might be attributed to the administration route—intramuscular.

Due to the infection mode of *S. mutans*, mucosal immunity shall be preferable for developing an effective vaccine. Unfortunately, numerous studies have shown that PAc without an appropriate adjuvant is a weak immunogen when given via the mucosal routes. In order to address this, Saito et al. (Protective Immunity to *Streptococcus mutans* Induced by Nasal Vaccination with Surface Protein Antigen and Mutant Cholera Toxin Adjuvant. *Journal of Infectious Diseases* 183, 823-826 (2001)) purified PAc from the cultural supernatant of *S. mutans*. Nasal administration of FAc and mutant cholera toxin (mCT) induced PAc-specific IgA antibodies with the titers in saliva (\log_2 , 6.1+/-1.7) and in nasal wash samples (\log_2 , 8.2+/-1.5). Ag-specific immune responses induced by nasal immunization with PAc with mCT provided significant inhibition of colonization of *S. mutans*. However, this study has critical shortcomings. First, the antigen PAc used was not an expressed recombinant protein; direct purification from bacterial cultures could not rule out the possibility that the shown effectiveness resulted from the contamination; this is

2

similar to Lehner study described above. Second, cholera toxin (CT) is toxic; although it has been studied for many years, it is still far away from human uses. Finally, the effectiveness of protection against dental caries was not directly shown.

In summary, while the prior arts have indicated that PAc might be a possible antigen for developing vaccines against the dental caries caused by *S. mutans*, there is no teaching or suggestion of what an effective mucosal vaccine against the dental caries caused by *S. mutans* should be.

Therefore, there is an imperative need to develop an effective mucosal vaccine against the dental caries caused by *S. mutans*.

SUMMARY OF THE INVENTION

The present invention provides a vaccine composition for dental caries caused by *S. mutans* infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of *S. mutans* and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by *S. mutans* by administering to a subject the vaccine composition.

The objectives and advantages of the invention will become apparent from the following detailed description of preferred embodiments thereof in connection with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Preferred embodiments according to the present invention will now be described with reference to the Figures, in which like reference numerals denote like elements.

FIG. 1 shows the purified PAc and FliC (flagellin); (A) lane 1: Western blot of purified PAc probed with HRP-conjugated anti-His-tag antibody; lane 2: Coomassie blue stain of SDS-PAGE of the purified recombinant PAc; (B) Lane 3: Coomassie blue stain of SDS-PAGE of the recombinant FliC; and lane 4: Western blot of purified FliC probed with HRP-conjugated anti-His-tag antibody.

FIG. 2 is a graph showing the titers of serum anti-PAc IgG, serum anti-PAc IgA and saliva anti-PAc IgA antibodies from four groups of mice intranasally immunized with: (1) PBS; (2) 10 μ g PAc; (3) 10 μ g PAc+1 μ g FliC; (4) 10 μ g PAc+5 μ g FliC, where the data are expressed as means \pm standard deviation.

FIG. 3 is a graph showing the titers of (a) serum anti-PAc IgG, (b) serum anti-PAc IgA and (c) saliva anti-PAc IgA antibodies from four groups of rats intranasally immunized with: (1) PBS; (2) 5 μ g FliC; (3) 20 μ g PAc+5 μ g FliC; (4) 40 μ g PAc+5 μ g FliC, where the data are expressed as means \pm standard deviation.

FIG. 4 shows three exemplary pictures illustrating (A) median-sagittal section of normal molar teeth of rat (right maxillary part of lingual side) and (B) median-sagittal section of carious molar teeth of rat challenged and infected by *S. mutans* Ingbritt (right mandible part of lingual side), where dental caries of different levels are indicated by arrows in the pictures. (C) median-sagittal section of molar teeth of 20 μ g PAc+5 μ g FliC immunized rat subsequently challenged with *S. mutans* Ingbritt (right mandible part of lingual side). Mild carious spot could be observed sporadically and one was indicated by arrowhead.

FIG. 5 contains two graphs showing (A) overall score of dental caries of four groups of rats, each dot represents cari-

3

ous level of each rat and (B) Keyes score of dental caries in different parts of molar teeth of four groups rats intranasally immunized with: (1) PBS; (2) 5 μ g FliC; (3) 20 μ g Pac+5 μ g FliC; (4) 40 μ g Pac+5 μ g FliC. Values are expressed as the means plus standard deviations. *Significantly different from negative control group ($p<0.05$). **Significantly different from negative control group ($p<0.01$). ***Significantly different from negative control group ($p<0.001$). Symbols: , Enamel lesion; , Slight dental lesion; , Moderate dental lesion.

FIG. 6 illustrates the construction of pET28a-KF-Pac plasmid.

FIG. 7 illustrates the construction of pET28-KFD2-Pac plasmid.

FIG. 8 shows the SDS-PAGE picture (A) and Western blot picture (B) of purified Pac, KF-Pac and KFD2-Pac.

FIG. 9 is a graph showing serum anti-Pac IgG, serum anti-Pac IgA and saliva anti-Pac IgA titers in groups of mice immunized with PBS, Pac, KF+Pac, KF-Pac, or KFD2-Pac respectively, where the data are expressed as means \pm standard deviation.

FIG. 10 includes three graphs showing (A) serum anti-Pac IgG, (B) serum anti-Pac IgA and (C) saliva anti-Pac IgA titers in groups of mice immunized with PBS, 1 μ gPac+0.7 μ gKF, 1.4 μ gKFD2-Pac, 2.5 μ gPac+1.8 μ gKF, 3.5 μ gKFD2-Pac, 5 μ gPac+3.5 μ gKF, 7 μ gKFD2-Pac, 10 μ gPac+7 μ gKF, 14 μ gKFD2-Pac, 20 μ gPac+14 μ gKF, or 28 μ gKFD2-Pac respectively, where the data are expressed as means \pm standard deviation.

FIG. 11 includes three graphs showing (A) serum anti-Pac IgG, (B) serum anti-Pac IgA and (C) saliva anti-Pac IgA titers in groups of mice immunized with PBS, Pac, KF+Pac, KF-Pac, or KFD2-Pac respectively, where the data are expressed as means \pm standard deviation.

FIG. 12 is a graph showing the Keyes scores of five groups of rats immunized with PBS, Pac, KF-Pac, KF-Pac or KFD2-Pac respectively, each point represents the caries score of each rat, where the horizontal values are means \pm standard deviation.

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of certain embodiments of the invention.

Throughout this application, where publications are referenced, the disclosures of these publications are hereby incorporated by reference, in their entireties, into this application in order to more fully describe the state of art to which this invention pertains.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, for example, *Molecular Cloning: A Laboratory Manual*, second edition (Sambrook et al., 1989); *Current Protocols in Molecular Biology* (F. M. Ausubel et al., eds., 1987).

One aspect of the present invention provides a vaccine used as a preventive or therapeutic medicament against the dental caries caused by *S. mutans* infection. In one embodiment, the vaccine of the present invention comprises a surface antigen (Pac) from *S. mutans* and flagellin as adjuvant. In certain

4

embodiments, the Pac and flagellin are expressed as a single recombinant protein, for example the Pac is inserted into the hypervariable domain of the flagellin or substitutes partial or whole hypervariable domain of the flagellin; in certain embodiments, the Pac and flagellin are tagged or conjugated with complementary moieties that bring these two molecules into close proximity; in certain embodiments, the Pac and flagellin are conjugated; in certain

embodiments, the Pac antigen is the full length protein (SEQ ID NO 2). In certain embodiments, the Pac antigen is an edited version of the full length protein where the edited version comprises the main antigenic epitopes. The edited version means that one or more main antigenic epitopes of Pac are expressed in a recombinant protein, where the epitopes are either directly coupled or separated by a number of amino acids so long to maintain their antigenic conformation.

A "variant" used throughout this application refers to a polypeptide that is functional and has at least 90% identity with the sequences identified in the Sequence Listing, more preferably has at least 95% identity. For example, for Pac, a variant of Pac refers to a polypeptide that is antigenic useful for inducing immune response to Pac and has at least 90% identity with sequence listed in SEQ ID NO 1.

In certain embodiments, the fusion protein comprises a cleavable linker that is disposed between the Pac and purification tag, affording the removal of the tag from the fusion protein by chemical or enzymatic treatment of the fusion protein. It is apparent that the cleavable linker can be disposed at any site of the fusion protein according to a user's desire. In the expression vectors, the cleavable linker comprises a DNA sequence which codes for an amino acid or a sequence of amino acids which can be cleaved chemically or enzymatically at its C-terminal.

Examples of chemical agents useful for cleaving proteins are cyanogen bromide, 2-(2-nitrophenylsulfenyl)-3-bromo-3'-methylindolinium (BNPS-skatole), hydroxylamine, and the like. Cyanogen bromide cleaves proteins at the C-terminal of a methionine residue. BNPS-skatole cleaves at the C-terminal of a tryptophan residue. Hydroxylamine cleaves at the C-terminal of the moiety -Asn-Z- in which Z is Gly, Leu, or Ala.

Examples of enzymatic agents useful for cleavage are trypsin, papain, pepsin, plasmin, thrombin, enterokinase, and the like. Each effects cleavage at a particular amino acid sequence which it recognizes. Enterokinase, for example, recognizes the amino acid sequence -(Asp)_n-Lys- in which n is an integer from 2 to 4.

In certain embodiments, the fusion protein comprises one or more other purification tags. For example, six histidine residues are fused to the Pac at its N- or C-terminals, allowing purification of the Pac by a Ni²⁺ column. After the purification, six histidine residues can be removed by chemical or enzymatic cleavage. In fact, any known purification tag is suitable here including myc tag, Flag-peptide, KT3 epitope, alpha-tubulin epitope, T7 gene 10 protein peptide tag, glutathione-S-transferase (GST), strep-tag, bovine pancreatic trypsin inhibitor (BPTI), and maltose binding protein (MBP).

As discussed above, the techniques for expression vector cloning, construction and amplification are well known to those skilled in the art. Therefore, the expression vectors for Pac or FliC can be constructed by routine procedures; no further details are provided herein in order not to obscure the present invention.

The mucosal surface is the most important protective barrier to the body, which is due to the predominant isotype, S-IgA, a product of the common mucosal immune system (CMIS). There are several mucosal routes which are developed for local immunization including oral, gastric instillation, intranasal, pulmonary, vaginal and rectal routes. Compared with other mucosal routes, intranasal immunization has more advantages, like being more convenient to administer and being easier to elicit mucosal response especially in oral cavity. Intranasal administration is a convenient delivery route and has been demonstrated to be effective in inducing salivary IgA responses in anti-caries vaccination.

As used herein, a "vaccine" is an antigenic preparation that is used to induce an immune response in individuals. A vaccine can have more than one constituent that is antigenic.

As used herein, "non-protein carriers" are carriers which are not proteins and can be used to achieve multimeric display of PAc and flagellin antigenic epitopes.

The term "microcarrier" refers to a particulate composition which is insoluble in water and which has a size of less than about 150, 120 or 100 μm , more commonly less than about 50-60 μm , and may be less than about 10 μm or even less than about 5 μm . Microcarriers include "nanocarriers," which are microcarriers have a size of less than about 1 μm , preferably less than about 500 nm. Microcarriers include solid phase particles such particles formed from biocompatible naturally occurring polymers, synthetic polymers or synthetic copolymers, although microcarriers formed from agarose or cross-linked agarose may be included in the definition of microcarriers herein as well as other bio degradable materials known in the art. Solid phase microcarriers are formed from polymers or other materials which are non-erodible and/or non-degradable under mammalian physiological conditions, such as polystyrene, polypropylene, silica, ceramic, polyacrylamide, gold, latex, hydroxyapatite, and ferromagnetic and paramagnetic materials. Biodegradable solid phase microcarriers may be formed from polymers which are degradable (e.g., poly(lactic acid), poly(glycolic acid) and copolymers thereof, such as poly(D, L-lactide-co-glycolide) or erodible (e.g., poly(ortho esters such as 3,9-diethylidene-2,4,8,10-tetraoxaspiro [5,5] undecane (DETOSU) or poly(anhydrides), such as poly(anhydrides) of sebacic acid) under mammalian physiological conditions. Microcarriers are typically spherical in shape, but microcarriers which deviate from spherical shape are also acceptable (e.g., ellipsoidal, rod-shaped, etc.). Microcarriers may also be liquid phase (e.g., oil or lipid based), such as liposomes, iscoms (immune-stimulating complexes, which are stable complexes of cholesterol, phospholipid and adjuvant-active saponin) without antigen, or droplets or micelles found in oil-in-water or water-in-oil emulsions, such as MF59. Biodegradable liquid phase microcarriers typically incorporate a biodegradable oil, a number of which are known in the art, including squalene and vegetable oils. The term "nonbiodegradable", as used herein, refers to a microcarrier which is not degraded or eroded under normal mammalian physiological conditions. Generally, a microcarrier is considered nonbiodegradable if it no degraded (i.e., loses less than 5% of its mass or average polymer length) after a 72 hour incubation at 37° C. in normal human serum.

An "individual" or "subject" is a vertebrate, such as avian, preferably a mammal, such as a human. Mammals include, but are not limited to, humans, non-human primates, farm animals, sport animals, experimental animals, rodents (e.g., mice and rats) and pets.

An "effective amount" or a "sufficient amount" of a substance is that amount sufficient to effect a desired biological effect, such as beneficial results, including clinical results,

and as such, an "effective amount" depends upon the context in which it is being applied. In the context of this invention, an example of an effective amount of a composition comprising the desired antigen is an amount sufficient to induce an immune response in an individual. An effective amount can be administered in one or more administrations.

"Stimulation" of an immune response, such as humoral or cellular immune response, means an increase in the response, which can arise from eliciting and/or enhancement of a response.

As used herein, and as well-understood in the art, "treatment" is an approach for obtaining beneficial or desired results, including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of infection, stabilized (i.e., not worsening) state of infection, amelioration or palliation of the infectious state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.

According to the present invention, a "dose" of a vaccine composition, is a quantity of vaccine composition that is administered at a particular point in time. A "dose" may also be a quantity of vaccine composition that is gradually administered to an individual using an extended release formulation and/or apparatus. In certain embodiments of the present invention, two or more doses of the vaccine composition are administered to an individual at different time points.

According to the present invention, an "immunologically-effective amount" of PAc is an amount of PAc which will induce complete or partial immunity in a treated animal against subsequent challenge with *S. mutans*. Complete or partial immunity can be assessed by observing, either qualitatively or quantitatively, the clinical symptoms of dental caries in a vaccinated individual as compared to an unvaccinated individual after being challenged. Where the clinical symptoms in a vaccinated individual after challenge are reduced, lessened or eliminated as compared to the symptoms observed in an unvaccinated individual after a similar or identical challenge, the amount of PAc that was administered to the vaccinated individual is regarded as an "immunologically-effective amount".

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The dose of PAc is between 0.1 and 60 μg . Preferably, the dose of PAc is between 0.25 and 15 μg . Most preferably, the dose is between 1 and 3 μg .

The vaccine of the present invention may further comprise another adjuvant. Non-limiting examples of suitable adjuvants include squalene and squalene (or other oils of animal origin); block copolymers; detergents such as Tween-80; Quil A, mineral oils such as Drakeol or Marcol, vegetable oils such peanut oil; *Corynebacterium*-derived adjuvants such as *Corynebacterium parvum*; *Mycobacterium bovis* (Bacille Calmette and Guerin or BCG); interleukins such as interleukin 2 and interleukin 12; monokines such as interleukin 1; tumor necrosis factor; interferons such as gamma interferon; surface active substances such as hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin; oil emulsions; and mineral gels such as aluminum phosphate, aluminum hydroxide or alum.

A therapeutic composition of the present invention can be formulated in an excipient that the object to be treated can tolerate. Examples of such excipients include water, saline,

Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical or biological stability. Examples of buffers include phosphate buffer, bicarbonate buffer, and Tris buffer, while examples of stabilizers include A1/A2 stabilizer.

Acceptable protocols to administer therapeutic compositions in an effective manner include individual dose size, number of doses, frequency of dose administration, and mode of administration. Determination of such protocols can be accomplished by those skilled in the art, and examples are disclosed herein.

Administering or administer is defined as the introduction of a substance into the body of an individual and includes oral, nasal, ocular, rectal, vaginal and parenteral routes. Compositions may be administered individually or in combination with other agents via any route of administration, including but not limited to subcutaneous (SQ), intramuscular (IM), intravenous (IV), intraperitoneal (IP), intradermal (ID), via the nasal, ocular or oral mucosa (IN) or orally.

The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial response in a patient over an appropriate period of time. The quantity of agents to be administered may depend on the subject to be treated inclusive of the age, sex, weight and general health condition thereof.

Immunotherapeutic compositions of the invention may be used to prophylactically or therapeutically immunize individuals such as humans. However, other animals are contemplated, preferably vertebrate animals including domestic animals such as livestock and companion animals.

Pharmaceutically acceptable carriers preferred for use in the present invention may include sterile aqueous of non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose", and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

The following examples are provided for the sole purpose of illustrating the principles or implementation of the present invention; they are by no means intended to limit or narrow the scope of the present invention.

EXAMPLE 1

Bacteria

S. mutans Ingbritt was grown in brain heart infusion (BHI) broth for 18 h at 37° C. under anaerobic condition, and the cultures were used for infection or stored in glycerol-BHI broth at -70° C. until used.

Expression and Purification of recombinant PAc and FliC pVAX1 is the only vector authorized by the US Food and Drug Administration in clinical trials.

The genes and proteins of PAc and flagellin used are represented by SEQ ID NO 1 (coding sequence of PAc), SEQ ID NO 2 (PAc protein), SEQ ID NO 3 (coding sequence of flagellin), and SEQ ID NO 4 (flagelling protein). The frag-

ment of PAc (aa 219-680) encoded by nucleotides (657-2694) and the FliC were amplified from pertinent bacterial strains and cloned into expression plasmid pET28a using conventional recombinant techniques, resulting in pET28a-PAc or pET28a-FliC respectively. The recombinant PAc and FliC proteins at their C-terminal were fused with a 6HisTag for facilitating purification. Expression plasmids pET28a-PAc or pET28a-FliC were respectively transformed into *E. coli* BL21 (DE3), and single positive clones were verified. The transformed bacteria were cultured overnight at 37° C. in Luria-Bertani (LB) broth with 50 µg/ml Kanamycin; bacteria of logarithmic phase were induced with 0.5 mM isopropyl β-D-thiogalactoside (IPTG). The expressed recombinant proteins were purified by affinity chromatography on a Ni-NTA column (Qiagen); the purified proteins were quantified by Bradford method and verified by Western blot with a murine anti-HisTag mAb (Qiagen) and a second horseradish-peroxidase-conjugated goat anti-mouse antibody (Pierce). The detection for Western blot was performed with the SuperSignal West Pico Chemiluminescent Substrate (Pierce), followed by imaging on a Versadoc 3000 Imager (Bio-Rad). Contaminated endotoxins and lipopolysaccharides (LPS) were removed using AffinityPak Detoxi Gel Endotoxin Removing Gel (Pierce). The contents of endotoxin and LPS in the final protein preparations were determined using Limulus assay (Associates of Cape Cod); the values were <0.001 EU/µg.

EXAMPLE 2

Immunization of Mice

For dose effect, four groups of 8-weeks-old female BALB/c mice (n=5) were intranasally (i.n.) immunized three times at 24-day intervals with (1) PBS, (2) 10 µg PAc, (3) 10 µg PAc+1 µg FliC, or (4) 10 µg PAc+5 µg FliC for each mouse with a volume of 10 µl, where all proteins were dissolved in PBS. Sera and saliva were collected 4 weeks after final immunization. Anesthetized animals were bled, and then sera were obtained from centrifugation of blood samples. Saliva samples were collected after intraperitoneal (i.p.) injection of (50 µl for mice; 250 µl for rats) 200 µg/ml carbachol (Sigma) to stimulate flow. The saliva samples needed to be centrifuged before antibody analysis. Sera and saliva were stored at -70° C. until they were assayed by ELISA.

For long-lasting effect, three groups of 8-week-old female BALB/c mice (n=5) were intranasally (i.n.) immunized three times at 24-day intervals with (1) PBS, (2) 10 µg PAc, or (3) 10 µg PAc+5 µg FliC for each mouse with a volume of 10 µl, where all proteins were dissolved in PBS. Sera and saliva were collected at indicated times after final immunization as described above.

For dose effects in rats, four groups of female Wistar rats (n=5) were intranasally (i.n.) immunized three times at 24-day intervals with: (1) PBS; (2) 5 µg FliC; (3) 20 µg PAc+5 µg FliC; (4) 40 µg PAc+5 µg FliC for each rat with a volume of 10 µl, where all proteins were dissolved in PBS. Salivary and blood samples were collected at week 3, 6, 9, 10.

EXAMPLE 3

Experimental Rat Model

Six groups of female Wistar rats (n=5) were weaned at 18 days of age and fed with cariogenic diet, Keyes 2000. Antibiotics (ampicillin, chloramphenicol, and carbenicillin, 1.0 g/kg diet or water) were added from days 20 to 22 to temporarily suppress the oral flora to facilitate cariogenic bacterial

9

colonization. From days 24 to 26, the rats were orally challenged with 1×10^9 CFU of *S. mutans* Ingbritt by the use of swabs presoaked with the bacterial solution. Bacterial samples of the tooth surfaces were examined to verify that each rat was infected.

The scheme for therapeutic studies was as follows. Days 0-3 were for adaptive feeding; days 4-8 for elimination of oral bacteria by feeding with antibiotics; days 9-14 for planting *S. mutans* onto teeth; day 14 for prime vaccination; days 39 and 64 for boosting. The scheme for preventive studies was as follows. Days 0-3 were for adaptive feeding; Day 3 for prime vaccination; Days 28 and 52 for boosting; Days 35-40 for elimination of oral bacteria by feeding with antibiotics; days 41-46 for planting *S. mutans* onto teeth. Four groups of rats were intranasally immunized with: (1) PBS; (2) 5 μ g FliC; (3) 20 μ g PAc+5 μ g FliC; (4) 40 μ g PAc+5 μ g FliC, respectively, following the schemes as described above.

EXAMPLE 4

Antibody Analysis

For murine samples, specific saliva secretory IgA (S-IgA) and serum IgG and IgA were detected by ELISA. Polystyrene 96-well ELISA flat-bottom microplates (Greiner bio-one, Germany) were coated at 37° C. for 3 h with 100 μ l PAc (5 μ g/ml in carbonate buffer, pH 9.6). After blocked with PBS containing 1% bovine serum albumin (BSA) overnight at 4° C., the plates were washed three times, and serially diluted saliva or sera were added to each well and incubated at 37° C. for 2 h. The plates were washed six times with PBS containing 0.05% Tween 20 (PBST) before the addition of 100 μ l alkaline phosphatase-conjugated goat anti-mouse IgG and goat anti-mouse IgA (diluted 1:2000, SouthernBiotech). After washed six times with PBST, 100 μ l phosphate substrate (p-nitrophenylphosphate) was then added to each well. After incubated at 37° C. for 30 min, optical density at 405 nm (OD 405) was recorded. The end-point titer was defined as the highest dilution with an absorbance=0.1 over the absorbance of the sham control (no sample added).

For rat samples, Polystyrene 96-well ELISA flat-bottom microplates (Greiner bio-one, Germany) were coated at 37° C. for 3 h with 100 μ l PAc (5 μ g/ml in carbonate buffer, pH 9.6). After blocked with PBS containing 1% bovine serum albumin (BSA) overnight at 4° C., the plates were washed three times, and serially diluted saliva or sera were added to each well and incubated at 37° C. for 2 h. Each well was washed again with PBST, and then treated with 100 μ l quantities of goat anti-rat IgG or IgA (1:1000; Sigma), incubated for 2 h at 37° C., and washed again. Next, a 100 μ l quantity of alkaline-phosphatase-conjugated rabbit anti-rat IgG (1:10,000; SouthernBiotech) was added to each well and incubated for 5 h at 37° C., followed by phosphate substrate (p-nitrophenylphosphate) for 30 min at 37° C. Optical density (OD) readings were taken at 405 nm. The end-point titer was defined as the highest dilution with an absorbance=0.1 above that of the sham control (no sample added).

EXAMPLE 5

Rat Caries Assessment

After collecting the sera and saliva samples, rats were sacrificed and mandibles were removed, cleaned, and stained with murexide. Then the molar teeth were washed and sectioned and the caries levels were determined by the Keyes method. The extension and depth of carious lesions were

10

scored as enamel (E), superficial dental (Ds), and moderate dental (Dm) involvement. The overall carious score was the sum of E, Ds and Dm scores.

EXAMPLE 6

Statistical Analysis

Statistical differences were analyzed by using the Student t test. All animal experiments were repeated at least three times, and results from a representative experiment are shown.

EXAMPLE 7

Results

The recombinant PAc and FliC were purified and verified by anti-PAc and anti-His-tag antibody as an 85 kD band (FIG. 1, lane 1) and a 52 kD band (FIG. 1, lane 4).

Referring to FIG. 2, there is provided a graph showing the antibody titers from the mice that were intranasally immunized with (1) PBS, (2) 10 μ g PAc, (3) 10 μ g PAc+1 μ g FliC, or (4) 10 μ g PAc+5 μ g FliC. The results showed that FliC was a potent enhancer for augmenting the anti-PAc antibody titers in the sera and saliva, and more importantly, in the presence of FliC, PAc was capable of inducing high level of specific anti-PAc IgG and IgA antibodies in both sera and saliva.

Referring to FIG. 3, there are provided graphs showing the titers of (a) serum anti-PAc IgG, (b) serum anti-PAc IgA, and (c) saliva anti-PAc IgA antibodies from four groups of rats intranasally immunized with: (1) PBS; (2) 5 μ g FliC; (3) 20 μ g PAc+5 μ g FliC; (4) 40 μ g PAc+5 μ g FliC, where the data are expressed as means \pm standard deviation. The results from the rats were in line with the ones from the mice, showing that FliC was a potent enhancer for augmenting the anti-PAc antibody titers in the sera and saliva, and more importantly, in the presence of FliC, PAc was capable of inducing high level of specific anti-PAc IgG and IgA antibodies in both sera and saliva.

Now referring to FIG. 4, there are provided exemplary pictures illustrating (a) median-sagittal section of normal molar teeth of rat (right maxillary part of lingual side), (b) median-sagittal section of carious molar teeth of rat infected by *S. mutans* Ingbritt (right mandible part of lingual side), where dental caries of different levels are indicated by arrows in the picture, and (c) median-sagittal section of carious molar teeth of rat immunized first with PAc and FliC composition and then infected by *S. mutans* Ingbritt (right mandible part of lingual side), where minor dental caries is indicated by an arrow in the picture. It was evident that the rat model was useful because artificial dental caries were induced in the infected rats.

Now referring to FIG. 5, there are provided two graphs showing (A) overall score of dental caries of four groups of rats, each dot represents carious level of each rat and (B) Keyes score of dental caries in different parts of molar teeth of four groups rats intranasally immunized with: (1) PBS; (2) 5 μ g FliC; (3) 20 μ g PAc+5 μ g FliC; (4) 40 μ g PAc+5 μ g FliC. Values are expressed as the means plus standard deviations. *Significantly different from negative control group ($p < 0.05$). **Significantly different from negative control group ($p < 0.01$). ***Significantly different from negative control group ($p < 0.001$). Symbols: , Enamel lesion; , Slight dental lesion; , Moderate dental lesion.

11

As for overall carious lesions (FIG. 5A), rats of group 3 and 4 immunized via intranasal routes had fewer lesions than those of group 1 and 2. There are significant differences between group 4 and group 1 ($p<0.01$), group 4 and group 2 ($p<0.001$), group 5 and group 1 ($p<0.001$), group 5 and group 2 ($p<0.001$). The rats immunized with 40 μg PAc and 5 μg FliC through intranasal routes showed the least lesions. With regard to enamel, superficial dentinal, moderate dentinal lesions, there are also significant differences (FIG. 5B). As for enamel lesions (E), there are significant differences between group 4 and group 1 ($p<0.001$), group 4 and group 2 ($p<0.001$), group 5 and group 1 ($p<0.001$), group 5 and group 2 ($p<0.001$); for superficial dentinal lesions (Ds), there are significant differences between group 4 and group 1 ($p<0.05$), group 4 and group 2 ($p<0.01$), group 5 and group 1 ($p<0.01$), group 5 and group 2 ($p<0.001$). Due to low carious score for moderate dentinal lesions, there is no statistically significant difference between these groups, but we still can see less mean score for group 4 and group 5 compared with the former three groups.

The average carious scores of group 1, 2, 3, and 4 are 54.2, 54.4, 28 and 23.8 respectively. Therefore, rats of group 4 and 5 had 48% and 56% reductions respectively.

EXAMPLE 8

Construction of pET28a-KF-Pac Plasmid

KF-Pac nucleotide sequence (SEQ ID NO 5) and amino acid sequence (SEQ ID NO 6), where KF denotes the flagellin derived from *E. coli* (SEQ ID NO 15 denotes KF nucleotide sequence, SEQ ID NO 16 denotes KF amino acid sequence). First, amplified KF and Pac fragments by PCR, where the up-stream primer for KF is 5' GCGCCATG GCACAAGT-CATTAATACC 3' (SEQ ID NO 7), the down-stream primer for KF is 5' AACAAAGCTTACCCTGCAGCAGAGACAGAAC 3' (SEQ ID NO 8), and up- and down-stream primers were introduced Nco I or Hind III enzymatic sites respectively (the enzymatic sites are highlighted); the up-stream primer for Pac is 5' TCAAAGCTTGGAACCAATGCTGCCAATC 3' (SEQ ID NO 9), the down-stream primer for Pac is 5' ACGTCTCGAGCTCATAAGTTGGCTCAACAG 3' (SEQ ID NO 10), the up- and down-stream primers were introduced Hind III or Xho I enzymatic sites respectively. pET28a was chosen as the vector; ligated these two fragments sequentially into the vector; the resultant ligated product was used to transform BL21(DE3)star; picked positive clones for verification by enzymatic digestion and sequencing. The correct recombinant plasmid was designated as pET28a-KF-Pac; the expression product KF-Pac contained a (His)₆ tag at its C-terminal. The plasmid construction is illustrated in FIG. 6, where KF fragment contained 1494 bases encoding 498 amino acids (1-498), Pac fragment contained 2085 bases encoding 695 amino acids (501-1195); KF and Pac fragments were connected by 2 amino acids.

EXAMPLE 9

Construction of pET28a-KFD2-Pac Plasmid

KFD2-Pac nucleotide sequence (SEQ ID NO 11) and amino acid sequence (SEQ ID NO 12). First, amplified Pac fragment; the up-stream primer is 5' TATAGCTAGCGGAACCAATGCTGCCAATC 3' (SEQ ID NO 13), the down-stream primer is 5' ATTAGGATCCGTCGTCTCATAAGT-TGGCTC 3' (SEQ ID NO 14); the up- and down-stream primers were introduced Nhe I or BamH I enzymatic sites

12

respectively (the enzymatic sites are highlighted). Then ligated the fragment into the constructed pET28a-KFD2 plasmid; the ligated product was used to transform BL21(DE3) star; picked positive clones for verification by enzymatic digestion and sequencing. The correct recombinant plasmid was designated as pET28a-KFD2-Pac; the expression product KFD2-Pac contained a (His)₆ tag at its C-terminal. The plasmid construction is illustrated in FIG. 7, where Pac fragment contained 2061 bases encoding 687 amino acids (174-860).

FIG. 8 shows the SDS-PAGE picture (A) and Western blot picture (B) of purified Pac, KF-Pac and KFD2-Pac.

EXAMPLE 10

Five groups of mice were intranasally immunized: (1) PBS; (2) 1 μg PAc; (3) 1 μg PAc+0.7 μg KF; (4) 1.7 μg KF-Pac; (5) 1.4 μg KFD2-Pac. After trice immunization, antibodies were analyzed as in Example 4. FIG. 9 is a graph showing serum anti-Pac IgG, serum anti-Pac IgA and saliva anti-Pac IgA titers, where the data are expressed as means \pm standard deviation.

EXAMPLE 11

Eleven groups of rats were intranasally immunized: (1) PBS; (2) 1 μg PAc+0.7 μg KF; (3) 1.4 μg KFD2-Pac; (4) 2.5 μg PAc+1.8 μg KF; (5) 3.5 μg KFD2-Pac; (6) 5 μg PAc+3.5 μg KF; (7) 7 μg KFD2-Pac; (8) 10 μg PAc+7 μg KF; (9) 14 μg KFD2-Pac; (10) 20 μg PAc+14 μg KF; (11) 28 μg KFD2-Pac. After trice immunization, antibodies were analyzed as in Example 4. FIG. 10 includes three graphs showing (A) serum anti-Pac IgG, (B) serum anti-Pac IgA and (C) saliva anti-Pac IgA titers, where the data are expressed as means \pm standard deviation.

EXAMPLE 12

Five groups of rats were intranasally immunized: (1) PBS; (2) 5 μg PAc; (3) 5 μg PAc+3.5 μg KF; (4) 8.5 μg KF-Pac; (5) 7 μg KFD2-Pac. After trice immunization, antibodies were analyzed as in Example 4. FIG. 11 includes three graphs showing (A) serum anti-Pac IgG, (B) serum anti-Pac IgA and (C) saliva anti-Pac IgA titers, where the data are expressed as means \pm standard deviation.

EXAMPLE 13

Five groups of rats were intranasally immunized: (1) PBS; (2) 5 μg PAc; (3) 5 μg PAc+3.5 μg KF; (4) 8.5 μg KF-Pac; (5) 7 μg KFD2-Pac. The immunized rats were prior infected; the infection dose was 2×10^9 CFU. 12 weeks after infection, the scores were calculated, and carious teeth were analyzed as in Example 5. FIG. 12 is a graph showing the Keyes scores of five groups of rats, each point represents the caries score of each rat, where the horizontal values are means \pm standard deviation.

While the present invention has been described with reference to particular embodiments, it will be understood that the embodiments are illustrative and that the invention scope is not so limited. Alternative embodiments of the present invention will become apparent to those having ordinary skill in the art to which the present invention pertains. Such alternate embodiments are considered to be encompassed within the scope of the present invention. Accordingly, the scope of the present invention is defined by the appended claims and is supported by the foregoing description.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 16

<210> SEQ ID NO 1

<211> LENGTH: 4689

<212> TYPE: DNA

<213> ORGANISM: *Streptococcus mutans*

<400> SEQUENCE: 1

```

atgaaagtca aaaaaactta cggttttcgt aaaagtaaaa ttagtaaaac actgtgtggt      60
gctgttctag gaacagtagc agcagtcctc gtagcaggac aaaaggtttt tgccgatgaa      120
acgaccacta ctagtgatgt agatactaaa gtagttggga cacaactggg aaatccagcg      180
accaatttgc cagaggctca agggagtgcg agtaaggaag ctgaacaaag tcaaaacca      240
gctggagaga caaatgggtc aataccagtt gaagtaccta aaactgatct tgatcaagca      300
gcaaaagatg ctaagtctgc tgggtgcaat gttgtccaag atgctgatgt taataaagga      360
actgttaaaa cagctgaaga agcagtcocaa aaagaaactg aaattaaaga agattacaca      420
aaacaagctg aggatattaa gaagacaaca gatcaatata aatcggatgt agctgctcat      480
gaggcagaag ttgctaaaat taaagctaaa aatcaggcaa ctaaagaaca gtatgaaaa      540
gatatggcag ctcataaagc cgaggttgaa cgcattaatg ctgcaaatgc tgccagtaaa      600
acagcttatg aatctaaatt ggctcaatat caagtagatt tagcagccgt tcaaaaaacc      660
aatgctgcc aatcaagcagc ctatcaaaaa gcccttgctg cttatcaggc tgaactgaaa      720
cgtgttcagg aagetaatgc agccgcaaaa gccgcttatg atactgctgt agcagcaaat      780
aatgccaaaa atacagaaat tgccgctgcc aatgaagaaa ttagaaaacg caatgcaacg      840
gccaaagctg aatatgagac taagttagct caatatcaag ctgaactaaa gcgtgttcag      900
gaagctaata cgcgcaacga agcagactat caagetaaat tgaccgccta tcaaacagag      960
cttgctcgcg ttcaaaaggc taatgcggat gctaaagcgg cctatgaagc agctgtagca      1020
gcaataaatg ccaaaaatgc ggcaactcaca gctgaaaata ctgcaattaa gcaacgcaat      1080
gagaatgcta aggcgactta tgaagctgca ctcaagcaat atgaggccga tttggcaacg      1140
gtgaaaaaag ctaatgcccg aaacgaagca gactatcaag ctaaattgac cgctatcaa      1200
acagagctcg ctcgcttca aaaaagcgaat gcggatgcta aagcggccta tgaagcagct      1260
gtagcagcaa ataatgcccg aaatgcagcg ctcacagctg aaaatactgc aattaagaag      1320
cgcaatgccc atgctaaagc tgattacgaa gcaaaacttg ctaagtatca agcagatctt      1380
gccaaatata aaaaagatgt agcagactat ccagtttaagt taaaggcata cgaagatgaa      1440
caagcttcta ttaaaactgc actggcagaa cttgaaaaac ataaaaatga agacggaaac      1500
ttaacagaac catctgctca aaatttggtc tatgatcttg agccaaatgc gaacttatct      1560
ttgacaacag atgggaagtt ccttaaggct tctgctgtgg atgatgcttt tagcaaaagc      1620
acttcaaaag caaaatata ccaaaaaatt cttcaattag atgatctaga taccactaac      1680
ttagaacaat ctaatgatgt tgcttctctc atggagcttt atgggaatgt tggatgataa      1740
gctggctggt caacgacagt aagcaataac tcacaggtta aatggggatc ggtactttta      1800
gagcgcggtc aaagcgcaac agctacatac actaacctgc agaattctta ttacaatggt      1860
aaaaagatgt ctaaaatgt ctacaagtat acagtggacc ctaagtccaa gtttcaagg      1920
caaaaggttt ggttaggtat tttaccgat ccaactttag gtgtttttgc ttccgcttat      1980
acaggtcaag ttgaaaaaaa cacttctatt tttatataaa atgaatttac tttctatgac      2040
gaagatggaa aaccaattaa ttttgataat gcccttctct cagtagcttc tcttaacgct      2100

```

-continued

gaaaataatt ctattgagat ggctaaagat tatacgggta aatttgtcaa aatctctgga	2160
tcactctatcg gtgaaaagaa tggcatgatt tatgctacag atactctcaa cttaggcag	2220
ggtcaagggtg gtgctcgttg gaccatgtat accagagcta gcgaaccggg atctggtctg	2280
gatagtccag atgcgcctaa ctcttggtat ggtgctgggtg ctatccgcat gtctggtcct	2340
aataacagtg tgactttggg tgctatctca tcaacacttg ttgtgctctg tgatcccaca	2400
atggcaattg aaactggcaa aaaaccaa atttggatt cttaaattgg taaaatccgt	2460
gcggttaatg ttctaaagt tactaaggaa aaaccacac ctccggttaa accaacagct	2520
ccaactaac caacttatga aacagaaaag ccattaaaac cggcaccagt agctccaaat	2580
tatgaaaagg agccaacacc gccgacaaga acaccgaatc aagcagagcc aaacaaacc	2640
acaccgccga cctatgaaac agaaaagccg ttggagccag cacctgtga gccaaagctat	2700
gaagcagagc caacaccgcc gacaaggaca ccggatcagg cagagccaaa taaaccaca	2760
ccgccgacct atgaaacaga aaagccgttg gagccagcac ctgttgagcc aagctatgaa	2820
gcagagccaa cgccaccgac accaacacca gatcaaccag aaccaaaaca acctgttgag	2880
ccaacttatg aggttattcc aacaccgccg actgatcctg tttatcaaga tctccaaca	2940
cctccatctg taccaactgt tcatttccat tactttaaac tagctgttca gccgcaggtt	3000
aacaaagaaa ttgaaaacaa taacgatgtt aatattgaca gaactttggt ggctaaacaa	3060
tctgttgta agttccagct gaagacagca gatctccctg ctggacgtga tgaacaact	3120
tcctttgtct tggtagatcc cctgccatct ggttatcaat ttaatcctga agctacaaaa	3180
gctgccagcc ctggccttga tgcgcttat gataatgcaa ctaatacagt caccttcaag	3240
gcaactgcag caactttggc tacgtttaat gctgatttga ctaaatcagt ggcaacgatt	3300
tatccaacag tggtcggaca agttcttaat gatggcgcaa cttataagaa taatttcacg	3360
ctcacagtca atgatgetta tggcattaaa tccaatggtt ttcgggtgac aactcctggt	3420
aaaccaaag atccagataa cccaaataat aattatatta aaccaactaa ggtaataaa	3480
aacgaaaatg gcgttggtat tgatggtaaa acagttcttg ccggttcaac gaattattat	3540
gagctaaact gggatttggg tcaatataaa aacgaaccgt cttcagcaga taccattcaa	3600
aaaggatttt actatgtaga tgattatcca gaagaagcgc ttgaattgag tcaggattta	3660
gtgaagatta cagatgctaa tggtaatgaa gttactggtg ttagtgtgga taattatact	3720
agtcttgaag cagcccctca agaaattaga gatgttcttt ctaaggcagg aattagacct	3780
aaaggtgctt tccaaatfff ccgtgccgat aatccaagag aattttatga tacttatgtc	3840
aaaactggaa ttgattttaa gattgtatca ccaatgggtg ttaaaaaaca aatgggacaa	3900
acaggcggca gttatgaaaa tcaagcttac caaattgact ttggtaatgg ttatgcatca	3960
aatatcgta tcaataatgt tcctaagatt aaccctaaga aagatgtgac cttaacactt	4020
gatccggctg atacaaaataa tgttgatggt cagactatcc cacttaatac agtctttaat	4080
taccgtttga ttggtggcat tatccctgca aatcactcag aagaactctt tgaatacaat	4140
ttctatgatg attatgatca aacaggagat cactatactg gtcagtataa agtttttgcc	4200
aaggttgata tcacttttaa agacggttct attatcaagt caggtgctga gttaactcag	4260
tatacgacag cggaaagtga taccgctaaa ggtgctatca caattaagtt caaggaagcc	4320
tttctgcggt ctgtttcaat tgattcagcc ttccaagctg aaagttatat ccaaatgaaa	4380
cgattgcgg ttggtacttt tgaataact tatattaata ctgtcaatgg ggtaacttac	4440

-continued

```

agttcaaata cagtgaaagac aactactcct gaggatccta cagaccctac tgatccgcaa 4500
gatccatcat caccgcgagac ttcaactgta attaactata aacctcaatc aactgcttat 4560
caaccaagct ctgttcaaga aacattacca aatacgggag taacaaacaa tgcttatatg 4620
cctttacttg gtattattgg cttagttact agttttagtt tgcttggttt aaaggctaag 4680
aaagattga 4689

```

```

<210> SEQ ID NO 2
<211> LENGTH: 1562
<212> TYPE: PRT
<213> ORGANISM: Streptococcus mutans

```

```

<400> SEQUENCE: 2

```

```

Met Lys Val Lys Lys Thr Tyr Gly Phe Arg Lys Ser Lys Ile Ser Lys
1          5          10          15
Thr Leu Cys Gly Ala Val Leu Gly Thr Val Ala Ala Val Ser Val Ala
20          25          30
Gly Gln Lys Val Phe Ala Asp Glu Thr Thr Thr Thr Ser Asp Val Asp
35          40          45
Thr Lys Val Val Gly Thr Gln Thr Gly Asn Pro Ala Thr Asn Leu Pro
50          55          60
Glu Ala Gln Gly Ser Ala Ser Lys Glu Ala Glu Gln Ser Gln Asn Gln
65          70          75          80
Ala Gly Glu Thr Asn Gly Ser Ile Pro Val Glu Val Pro Lys Thr Asp
85          90          95
Leu Asp Gln Ala Ala Lys Asp Ala Lys Ser Ala Gly Val Asn Val Val
100         105         110
Gln Asp Ala Asp Val Asn Lys Gly Thr Val Lys Thr Ala Glu Glu Ala
115         120         125
Val Gln Lys Glu Thr Glu Ile Lys Glu Asp Tyr Thr Lys Gln Ala Glu
130         135         140
Asp Ile Lys Lys Thr Thr Asp Gln Tyr Lys Ser Asp Val Ala Ala His
145         150         155         160
Glu Ala Glu Val Ala Lys Ile Lys Ala Lys Asn Gln Ala Thr Lys Glu
165         170         175
Gln Tyr Glu Lys Asp Met Ala Ala His Lys Ala Glu Val Glu Arg Ile
180         185         190
Asn Ala Ala Asn Ala Ala Ser Lys Thr Ala Tyr Glu Ser Lys Leu Ala
195         200         205
Gln Tyr Gln Val Asp Leu Ala Ala Val Gln Lys Thr Asn Ala Ala Asn
210         215         220
Gln Ala Ala Tyr Gln Lys Ala Leu Ala Ala Tyr Gln Ala Glu Leu Lys
225         230         235         240
Arg Val Gln Glu Ala Asn Ala Ala Ala Lys Ala Ala Tyr Asp Thr Ala
245         250         255
Val Ala Ala Asn Asn Ala Lys Asn Thr Glu Ile Ala Ala Ala Asn Glu
260         265         270
Glu Ile Arg Lys Arg Asn Ala Thr Ala Lys Ala Glu Tyr Glu Thr Lys
275         280         285
Leu Ala Gln Tyr Gln Ala Glu Leu Lys Arg Val Gln Glu Ala Asn Ala
290         295         300
Ala Asn Glu Ala Asp Tyr Gln Ala Lys Leu Thr Ala Tyr Gln Thr Glu
305         310         315         320
Leu Ala Arg Val Gln Lys Ala Asn Ala Asp Ala Lys Ala Ala Tyr Glu

```

-continued

325				330				335							
Ala	Ala	Val	Ala	Ala	Asn	Asn	Ala	Lys	Asn	Ala	Ala	Leu	Thr	Ala	Glu
			340							345				350	
Asn	Thr	Ala	Ile	Lys	Gln	Arg	Asn	Glu	Asn	Ala	Lys	Ala	Thr	Tyr	Glu
		355					360							365	
Ala	Ala	Leu	Lys	Gln	Tyr	Glu	Ala	Asp	Leu	Ala	Thr	Val	Lys	Lys	Ala
		370				375								380	
Asn	Ala	Ala	Asn	Glu	Ala	Asp	Tyr	Gln	Ala	Lys	Leu	Thr	Ala	Tyr	Gln
						390					395				400
Thr	Glu	Leu	Ala	Arg	Val	Gln	Lys	Ala	Asn	Ala	Asp	Ala	Lys	Ala	Ala
					405					410					415
Tyr	Glu	Ala	Ala	Val	Ala	Ala	Asn	Asn	Ala	Ala	Ala	Asn	Ala	Ala	Leu
			420							425					430
Ala	Glu	Asn	Thr	Ala	Ile	Lys	Lys	Arg	Asn	Ala	Asp	Ala	Lys	Ala	Asp
			435							440					445
Tyr	Glu	Ala	Lys	Leu	Ala	Lys	Tyr	Gln	Ala	Asp	Leu	Ala	Lys	Tyr	Gln
			450				455								460
Lys	Asp	Leu	Ala	Asp	Tyr	Pro	Val	Lys	Leu	Lys	Ala	Tyr	Glu	Asp	Glu
						470					475				480
Gln	Ala	Ser	Ile	Lys	Ala	Ala	Leu	Ala	Glu	Leu	Glu	Lys	His	Lys	Asn
											490				495
Glu	Asp	Gly	Asn	Leu	Thr	Glu	Pro	Ser	Ala	Gln	Asn	Leu	Val	Tyr	Asp
			500								505				510
Leu	Glu	Pro	Asn	Ala	Asn	Leu	Ser	Leu	Thr	Thr	Asp	Gly	Lys	Phe	Leu
			515												525
Lys	Ala	Ser	Ala	Val	Asp	Asp	Ala	Phe	Ser	Lys	Ser	Thr	Ser	Lys	Ala
			530				535								540
Lys	Tyr	Asp	Gln	Lys	Ile	Leu	Gln	Leu	Asp	Asp	Leu	Asp	Ile	Thr	Asn
						550					555				560
Leu	Glu	Gln	Ser	Asn	Asp	Val	Ala	Ser	Ser	Met	Glu	Leu	Tyr	Gly	Asn
						565					570				575
Phe	Gly	Asp	Lys	Ala	Gly	Trp	Ser	Thr	Thr	Val	Ser	Asn	Asn	Ser	Gln
			580												590
Val	Lys	Trp	Gly	Ser	Val	Leu	Leu	Glu	Arg	Gly	Gln	Ser	Ala	Thr	Ala
			595								600				605
Thr	Tyr	Thr	Asn	Leu	Gln	Asn	Ser	Tyr	Tyr	Asn	Gly	Lys	Lys	Ile	Ser
			610				615								620
Lys	Ile	Val	Tyr	Lys	Tyr	Thr	Val	Asp	Pro	Lys	Ser	Lys	Phe	Gln	Gly
						630					635				640
Gln	Lys	Val	Trp	Leu	Gly	Ile	Phe	Thr	Asp	Pro	Thr	Leu	Gly	Val	Phe
						645					650				655
Ala	Ser	Ala	Tyr	Thr	Gly	Gln	Val	Glu	Lys	Asn	Thr	Ser	Ile	Phe	Ile
			660								665				670
Lys	Asn	Glu	Phe	Thr	Phe	Tyr	Asp	Glu	Asp	Gly	Lys	Pro	Ile	Asn	Phe
			675								680				685
Asp	Asn	Ala	Leu	Leu	Ser	Val	Ala	Ser	Leu	Asn	Arg	Glu	Asn	Asn	Ser
			690				695								700
Ile	Glu	Met	Ala	Lys	Asp	Tyr	Thr	Gly	Lys	Phe	Val	Lys	Ile	Ser	Gly
						710					715				720
Ser	Ser	Ile	Gly	Glu	Lys	Asn	Gly	Met	Ile	Tyr	Ala	Thr	Asp	Thr	Leu
						725					730				735
Asn	Phe	Arg	Gln	Gly	Gln	Gly	Gly	Ala	Arg	Trp	Thr	Met	Tyr	Thr	Arg
											745				750

-continued

Ala Ser Glu Pro Gly Ser Gly Trp Asp Ser Ser Asp Ala Pro Asn Ser
755 760 765

Trp Tyr Gly Ala Gly Ala Ile Arg Met Ser Gly Pro Asn Asn Ser Val
770 775 780

Thr Leu Gly Ala Ile Ser Ser Thr Leu Val Val Pro Ala Asp Pro Thr
785 790 795 800

Met Ala Ile Glu Thr Gly Lys Lys Pro Asn Ile Trp Tyr Ser Leu Asn
805 810 815

Gly Lys Ile Arg Ala Val Asn Val Pro Lys Val Thr Lys Glu Lys Pro
820 825 830

Thr Pro Pro Val Lys Pro Thr Ala Pro Thr Lys Pro Thr Tyr Glu Thr
835 840 845

Glu Lys Pro Leu Lys Pro Ala Pro Val Ala Pro Asn Tyr Glu Lys Glu
850 855 860

Pro Thr Pro Pro Thr Arg Thr Pro Asn Gln Ala Glu Pro Asn Lys Pro
865 870 875 880

Thr Pro Pro Thr Tyr Glu Thr Glu Lys Pro Leu Glu Pro Ala Pro Val
885 890 895

Glu Pro Ser Tyr Glu Ala Glu Pro Thr Pro Pro Thr Arg Thr Pro Asp
900 905 910

Gln Ala Glu Pro Asn Lys Pro Thr Pro Pro Thr Tyr Glu Thr Glu Lys
915 920 925

Pro Leu Glu Pro Ala Pro Val Glu Pro Ser Tyr Glu Ala Glu Pro Thr
930 935 940

Pro Pro Thr Pro Thr Pro Asp Gln Pro Glu Pro Asn Lys Pro Val Glu
945 950 955 960

Pro Thr Tyr Glu Val Ile Pro Thr Pro Pro Thr Asp Pro Val Tyr Gln
965 970 975

Asp Leu Pro Thr Pro Pro Ser Val Pro Thr Val His Phe His Tyr Phe
980 985 990

Lys Leu Ala Val Gln Pro Gln Val Asn Lys Glu Ile Arg Asn Asn Asn
995 1000 1005

Asp Val Asn Ile Asp Arg Thr Leu Val Ala Lys Gln Ser Val Val
1010 1015 1020

Lys Phe Gln Leu Lys Thr Ala Asp Leu Pro Ala Gly Arg Asp Glu
1025 1030 1035

Thr Thr Ser Phe Val Leu Val Asp Pro Leu Pro Ser Gly Tyr Gln
1040 1045 1050

Phe Asn Pro Glu Ala Thr Lys Ala Ala Ser Pro Gly Phe Asp Val
1055 1060 1065

Ala Tyr Asp Asn Ala Thr Asn Thr Val Thr Phe Lys Ala Thr Ala
1070 1075 1080

Ala Thr Leu Ala Thr Phe Asn Ala Asp Leu Thr Lys Ser Val Ala
1085 1090 1095

Thr Ile Tyr Pro Thr Val Val Gly Gln Val Leu Asn Asp Gly Ala
1100 1105 1110

Thr Tyr Lys Asn Asn Phe Thr Leu Thr Val Asn Asp Ala Tyr Gly
1115 1120 1125

Ile Lys Ser Asn Val Val Arg Val Thr Thr Pro Gly Lys Pro Asn
1130 1135 1140

Asp Pro Asp Asn Pro Asn Asn Asn Tyr Ile Lys Pro Thr Lys Val
1145 1150 1155

-continued

Asn Lys 1160	Asn Glu	Asn Gly	Val 1165	Val Ile	Asp Gly	Lys Thr	Val Leu		
Ala Gly 1175	Ser Thr	Asn Tyr	Tyr 1180	Glu Leu	Thr Trp	Asp 1185	Leu Asp	Gln	
Tyr Lys 1190	Asn Asp	Arg Ser	Ser 1195	Ala Asp	Thr Ile	Gln 1200	Lys Gly	Phe	
Tyr Tyr 1205	Val Asp	Asp Tyr	Pro 1210	Glu Glu	Ala Leu	Glu 1215	Leu Arg	Gln	
Asp Leu 1220	Val Lys	Ile Thr	Asp 1225	Ala Asn	Gly Asn	Glu 1230	Val Thr	Gly	
Val Ser 1235	Val Asp	Asn Tyr	Thr 1240	Ser Leu	Glu Ala	Ala 1245	Pro Gln	Glu	
Ile Arg 1250	Asp Val	Leu Ser	Lys 1255	Ala Gly	Ile Arg	Pro 1260	Lys Gly	Ala	
Phe Gln 1265	Ile Phe	Arg Ala	Asp 1270	Asn Pro	Arg Glu	Phe 1275	Tyr Asp	Thr	
Tyr Val 1280	Lys Thr	Gly Ile	Asp 1285	Leu Lys	Ile Val	Ser 1290	Pro Met	Val	
Val Lys 1295	Lys Gln	Met Gly	Gln 1300	Thr Gly	Gly Ser	Tyr 1305	Glu Asn	Gln	
Ala Tyr 1310	Gln Ile	Asp Phe	Gly 1315	Asn Gly	Tyr Ala	Ser 1320	Asn Ile	Val	
Ile Asn 1325	Asn Val	Pro Lys	Ile 1330	Asn Pro	Lys Lys	Asp 1335	Val Thr	Leu	
Thr Leu 1340	Asp Pro	Ala Asp	Thr 1345	Asn Asn	Val Asp	Gly 1350	Gln Thr	Ile	
Pro Leu 1355	Asn Thr	Val Phe	Asn 1360	Tyr Arg	Leu Ile	Gly 1365	Gly Ile	Ile	
Pro Ala 1370	Asn His	Ser Glu	Glu 1375	Leu Phe	Glu Tyr	Asn 1380	Phe Tyr	Asp	
Asp Tyr 1385	Asp Gln	Thr Gly	Asp 1390	His Tyr	Thr Gly	Gln 1395	Tyr Lys	Val	
Phe Ala 1400	Lys Val	Asp Ile	Thr 1405	Phe Lys	Asp Gly	Ser 1410	Ile Ile	Lys	
Ser Gly 1415	Ala Glu	Leu Thr	Gln 1420	Tyr Thr	Thr Ala	Glu 1425	Val Asp	Thr	
Ala Lys 1430	Gly Ala	Ile Thr	Ile 1435	Lys Phe	Lys Glu	Ala 1440	Phe Leu	Arg	
Ser Val 1445	Ser Ile	Asp Ser	Ala 1450	Phe Gln	Ala Glu	Ser 1455	Tyr Ile	Gln	
Met Lys 1460	Arg Ile	Ala Val	Gly 1465	Thr Phe	Glu Asn	Thr 1470	Tyr Ile	Asn	
Thr Val 1475	Asn Gly	Val Thr	Tyr 1480	Ser Ser	Asn Thr	Val 1485	Lys Thr	Thr	
Thr Pro 1490	Glu Asp	Pro Thr	Asp 1495	Pro Thr	Asp Pro	Gln 1500	Asp Pro	Ser	
Ser Pro 1505	Arg Thr	Ser Thr	Val 1510	Ile Asn	Tyr Lys	Pro 1515	Gln Ser	Thr	
Ala Tyr 1520	Gln Pro	Ser Ser	Val 1525	Gln Glu	Thr Leu	Pro 1530	Asn Thr	Gly	
Val Thr 1535	Asn Asn	Ala Tyr	Met 1540	Pro Leu	Leu Gly	Ile 1545	Ile Gly	Leu	
Val Thr	Ser Phe	Ser Leu	Leu	Gly Leu	Lys Ala	Lys	Lys Asp		

-continued

1550	1555	1560	
<210> SEQ ID NO 3			
<211> LENGTH: 1521			
<212> TYPE: DNA			
<213> ORGANISM: Salmonella enterica			
<300> PUBLICATION INFORMATION:			
<308> DATABASE ACCESSION NUMBER: NC_004631.1			
<309> DATABASE ENTRY DATE: 2010-05-12			
<313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(1521)			
<400> SEQUENCE: 3			
atggcacaag	tcattaatac	aaacagcctg	tcgctggtga cccagaataa cctgaacaaa 60
tcccagtcg	cactgggac	tgctatcgag	cgtttgtctt cgggtctgcg tatcaacagc 120
gcgaaagacg	atgcggcagg	acagggcgatt	gctaaccgtt ttaccgcgaa catcaaaggt 180
ctgactcagg	cttcccgtaa	cgtaacgac	ggtatctcca ttgcgcgac cactgaaggc 240
gcgctgaacg	aaatcaacaa	caacctgcag	cggtgctgtg aactggcggg tcagtctgcg 300
aatggtacta	actcccagtc	tgacctcgac	tccatccagg ctgaaatcac ccagcgctg 360
aacgaaatcg	accgtgtatc	cgccagact	cagttcaacg gcgtgaaagt cctggcgcg 420
gacaacaccc	tgaccatcca	ggttggtgcc	aacgacggtg aaactatcga tattgattta 480
aaagaaatca	gctctaaaac	actgggactt	gataagctta atgtccaaga tgcctacacc 540
ccgaaagaaa	ctgctgtaac	cgttgataaa	actacctata aaaatggtac agatcctatt 600
acagcccaga	gcaatactga	tatccaaact	gcaattggcg gtggtgcaac gggggttact 660
ggggctgata	tcaaatttaa	agatggtcaa	tactatntag atgttaaagg cggtgcttct 720
gctggtgttt	ataaagccac	ttatgatgaa	actacaaga aagttaatat tgatacgact 780
gataaaaactc	cgttggcaac	tgcggaagct	acagctatcc ggggaacggc cactataacc 840
cacaacccaaa	ttgctgaagt	aacaaaagag	ggtgttgata cgaccacagt tgcggctcaa 900
cttgctgcag	caggggttac	tgccgccgat	aaggacaata ctagccttgt aaaactatcg 960
tttgaggata	aaaacggtaa	ggttattgat	ggtggctatg cagtgaaaa gggcgacgat 1020
ttctatgccc	ctacatatga	tgagaaaaca	ggtgcaatta ctgctaaac cactacttat 1080
acagatggta	ctggcgttgc	tcaaaactgga	gctgtgaaat ttggtggcgc aaatggtaaa 1140
tctgaagttg	ttactgctac	cgatggtaag	acttacttag caagcgacct tgacaaacat 1200
aaacttcagaa	caggcgggtga	gcttaagag	gtaatacag ataagactga aaaccactg 1260
cagaaaattg	atgctgcctt	ggcacagggt	gatacacctc gttctgacct ggggtcgggt 1320
cagaaccgtt	tcaactccgc	tatcaccaac	ctgggcaata ccgtaaataa cctgtcttct 1380
gcccgtagcc	gtatcgaaga	ttccgactac	gcaaccgaag tctccaacat gtctcgcgcg 1440
cagattctgc	agcaggcccg	tacctccgtt	ctggcgcgagg cgaaccagggt tccgcaaac 1500
gtcctctctt	tactgcgtta	a	1521

<210> SEQ ID NO 4
 <211> LENGTH: 506
 <212> TYPE: PRT
 <213> ORGANISM: Salmonella enterica
 <300> PUBLICATION INFORMATION:
 <308> DATABASE ACCESSION NUMBER: GeneID/1070204
 <309> DATABASE ENTRY DATE: 2010-05-12
 <313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(506)

<400> SEQUENCE: 4

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Leu Thr Gln Asn

-continued

1	5	10	15
Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr Ala Ile Glu Arg Leu	20	25	30
Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln	35	40	45
Ala Ile Ala Asn Arg Phe Thr Ala Asn Ile Lys Gly Leu Thr Gln Ala	50	55	60
Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Thr Glu Gly	65	70	80
Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Ala	85	90	95
Val Gln Ser Ala Asn Gly Thr Asn Ser Gln Ser Asp Leu Asp Ser Ile	100	105	110
Gln Ala Glu Ile Thr Gln Arg Leu Asn Glu Ile Asp Arg Val Ser Gly	115	120	125
Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ala Gln Asp Asn Thr Leu	130	135	140
Thr Ile Gln Val Gly Ala Asn Asp Gly Glu Thr Ile Asp Ile Asp Leu	145	150	160
Lys Glu Ile Ser Ser Lys Thr Leu Gly Leu Asp Lys Leu Asn Val Gln	165	170	175
Asp Ala Tyr Thr Pro Lys Glu Thr Ala Val Thr Val Asp Lys Thr Thr	180	185	190
Tyr Lys Asn Gly Thr Asp Pro Ile Thr Ala Gln Ser Asn Thr Asp Ile	195	200	205
Gln Thr Ala Ile Gly Gly Gly Ala Thr Gly Val Thr Gly Ala Asp Ile	210	215	220
Lys Phe Lys Asp Gly Gln Tyr Tyr Leu Asp Val Lys Gly Gly Ala Ser	225	230	240
Ala Gly Val Tyr Lys Ala Thr Tyr Asp Glu Thr Thr Lys Lys Val Asn	245	250	255
Ile Asp Thr Thr Asp Lys Thr Pro Leu Ala Thr Ala Glu Ala Thr Ala	260	265	270
Ile Arg Gly Thr Ala Thr Ile Thr His Asn Gln Ile Ala Glu Val Thr	275	280	285
Lys Glu Gly Val Asp Thr Thr Thr Val Ala Ala Gln Leu Ala Ala Ala	290	295	300
Gly Val Thr Gly Ala Asp Lys Asp Asn Thr Ser Leu Val Lys Leu Ser	305	310	315
Phe Glu Asp Lys Asn Gly Lys Val Ile Asp Gly Gly Tyr Ala Val Lys	325	330	335
Met Gly Asp Asp Phe Tyr Ala Ala Thr Tyr Asp Glu Lys Thr Gly Ala	340	345	350
Ile Thr Ala Lys Thr Thr Thr Tyr Thr Asp Gly Thr Gly Val Ala Gln	355	360	365
Thr Gly Ala Val Lys Phe Gly Gly Ala Asn Gly Lys Ser Glu Val Val	370	375	380
Thr Ala Thr Asp Gly Lys Thr Tyr Leu Ala Ser Asp Leu Asp Lys His	385	390	400
Asn Phe Arg Thr Gly Gly Glu Leu Lys Glu Val Asn Thr Asp Lys Thr	405	410	415
Glu Asn Pro Leu Gln Lys Ile Asp Ala Ala Leu Ala Gln Val Asp Thr	420	425	430

-continued

Leu Arg Ser Asp Leu Gly Ala Val Gln Asn Arg Phe Asn Ser Ala Ile
 435 440 445

Thr Asn Leu Gly Asn Thr Val Asn Asn Leu Ser Ser Ala Arg Ser Arg
 450 455 460

Ile Glu Asp Ser Asp Tyr Ala Thr Glu Val Ser Asn Met Ser Arg Ala
 465 470 475 480

Gln Ile Leu Gln Gln Ala Gly Thr Ser Val Leu Ala Gln Ala Asn Gln
 485 490 495

Val Pro Gln Asn Val Leu Ser Leu Leu Arg
 500 505

<210> SEQ ID NO 5
 <211> LENGTH: 3585
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: KP-Pac fusion

<400> SEQUENCE: 5

atggcacaag tcattaatac caacagcctc tcgctgatca ctcaaaataa tatcaacaag 60
 aaccagtctg cgctgtcgag ttctatcgag cgtctgtctt ctggcttgcg tattaacagc 120
 gcgaaggatg acgcagcggg tcaggcgatt gctaaccgtt tcacctctaa cattaaggc 180
 ctgactcagg cggcccgtaa cgccaacgac ggtatctccg ttgcgcagac caccgaaggc 240
 gcgctgtccg aaatcaacaa caacttacag cgtgtgctg aactgacggt acaggccact 300
 accggtacta actctgagtc tgatctgtct tctatccagg acgaaattaa atcccgtctg 360
 gatgaaattg acccgctatc tggtcagacc cagttcaacg gcgtgaaagt gctggcaaaa 420
 aatggctcca tgaaaatoca ggttggcgca aatgataacc agactatcac tatcgatctg 480
 aagcagattg atgctaaaac tcttggcctt gatggtttta gcgttaaaaa taacgataca 540
 gttaccacta gtgctccagt aactgctttt ggtgctacca ccacaaacaa tattaaactt 600
 actggaatta ccctttctac ggaagcagcc actgatactg gcggaactaa cccagcttca 660
 attgagggtg tttatactga taatggtaat gattactatg cgaaaatcac cggtggtgat 720
 aacgatggga agtattacgc agtaacagtt gctaattgat gtacagtgc aatggcgact 780
 ggagcaacgg caaatgcaac tgtaactgat gcaataacta ctaaagctac aactatcact 840
 tcaggcggta cacctgttca gattgataat actgcaggtt ccgcaactgc caacctggt 900
 gctgttagct tagtaaaact gcaggattcc aagggtaatg ataccgatac atatgcgctt 960
 aaagatacaa atggcaatct ttacgctgcg gatgtgaatg aaactactgg tgctgtttct 1020
 gttaaaacta ttacctatac tgactcttcc ggtgcgcgca gttctccaac cgcggtcaaa 1080
 ctgggcccgg atgatggcaa aacagaagtg gtcgatattg atggtaaaac atacgattct 1140
 gccgatttaa atggcggtaa tctgcaaaca ggtttgactg ctggtggtga ggctctgact 1200
 gctgttgcaa atggtaaaac cacggatccg ctgaaagcgc tggacgatgc tatcgcatct 1260
 gtagacaaat tccgttcttc cctcggtgcg gtgcaaaacc gtctggattc cgcggttacc 1320
 aacctgaaca acaccactac caacctgtct gaagcgcagt cccgtattca ggacgccgac 1380
 tatgcgaccg aagtgtccaa tatgtcgaaa gcgcagatca tccagcaggc cggtaaactcc 1440
 gtgttgccaa aagctaaoca ggtaccgcag caggttctgt ctctgctgca gggtaagctt 1500
 ggaaccaatg ctgccaatca agcagcctat caaaaagccc ttgctgctta tcaggctgaa 1560
 ctgaaacgtg ttcaggaagc taatgcagcc gccaaagccg cttatgatgc tgctgtagca 1620

-continued

```

gcaaataatg ccaaaaatac agaaattgcc gctgccaatg aagaaattag aaaacgcaat 1680
gcaacggcca aagctgaata tgagactaag ttagctcaat atcaagctga actaaagcgt 1740
gttcaggaag ctaatgccgc aaacgaagca gactatcaag ctaaattgac cgcctatcaa 1800
acagagcttg ctcgtgttca aaaagccaat gcggatgcta aagcgcacta tgaagcagct 1860
gtagcagcaa ataatgcca aaatgcggca ctcacagctg aaaatactgc aattaagcaa 1920
cgcaatgaga atgctaaggc gacttatgaa gctgcactca agcaatatga ggccgatttg 1980
gcagcgggta aaaaagctaa tgccgcaaac gaagcagact atcaagctaa attgaccgcc 2040
tatcaaacag agctcgctcg cgttcaaaaa gccaatgccc atgctaaagc ggccatgaa 2100
gcagctgtag cagcaataa tgccgcaaat gcagcgtca cagctgaaa tactgcaatt 2160
aagaagcgca atgcggatgc taaagctgat tacgaagcaa aacttgctaa gtatcaagca 2220
gatcttgcca aatatcaaaa agatttagca gactatccag ttaagttaaa ggcatcagaa 2280
gatgaacaaa cttctattaa agctgcactg gcagaacttg aaaaacataa aatgaagac 2340
ggaaacttaa cagaaccatc tgetcaaaat ttggtctatg atcttgagcc aaatgcgaac 2400
ttatctttga caacagatgg gaagtctctt aaggcttctg ctgtggatga tgcttttagc 2460
aaaagcactt caaaagcaaa atatgaccaa aaaattcttc aattagatga tctagatatc 2520
actaacttag aacaatctaa tgatgttget tcttctatgg agctttatgg gaattttggt 2580
gataaagctg gctgggcaac gacagtaagc aataactcac aggttaaatg gggatcggta 2640
cttttagagc gcggtcaaaag cgcaacagct acatacacta acctgcagaa ttcttattac 2700
aatggtaaaa agatttctaa aattgtctac aagtatacag tggaccctaa gtccaagttt 2760
caaggtcaaa aggtttgggt aggtattttt accgatccaa ctttaggtgt tttgcttct 2820
gcttatacag gtcaagtga aaaaaacact tctattttta taaaaatga attcactttc 2880
tatgacgaag atgaaaaacc aattaatttt gataatgccc ttctctcagt agcttctctt 2940
aaccgtgaac ataactctat tgagatggct aaagattata gtggtaaatt tgtcaaaatc 3000
tctggttcat ctattgggta aaagaatggc atgatttatg ctacagatc tcttaacttt 3060
aaacagggtg aaggtggctc tcgctggact atgtataaaa atagtcaagc tgggttcagga 3120
tgggatagtt cagatgcgcc gaattcttgg tatggagcag gggctattaa aatgtctggt 3180
cgaataaacc atgttactgt aggagcaact tctgcaacaa atgtaatgcc agtttctgac 3240
atgcctgttg ttctctgtaa ggacaatact gatggcaaaa aaccaaatat ttggatttct 3300
ttaaattgta aaatccgtgc ggtaaatggt cctaaagtta ctaaggaaaa acccacacct 3360
ccggttaaac caacagctcc aactaaacca acttatgaaa cagaaaagcc attaaaaccg 3420
gcaccagtag ctccaaatta tgaaggag ccaacaccgc cgacaaggac accggatcaa 3480
gcagagccaa acaaacccac accgccgacc tatgaaacag aaaagccgtt ggagccagca 3540
cctgttgagc caacttatga gctcagcac caccaccacc accac 3585

```

<210> SEQ ID NO 6

<211> LENGTH: 1195

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: KF-PAC fusion protein

<400> SEQUENCE: 6

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Ile Thr Gln Asn
1 5 10 15

-continued

Asn Arg Leu Asp Ser Ala Val Thr Asn Leu Asn Asn Thr Thr Thr Asn
 435 440 445
 Leu Ser Glu Ala Gln Ser Arg Ile Gln Asp Ala Asp Tyr Ala Thr Glu
 450 455 460
 Val Ser Asn Met Ser Lys Ala Gln Ile Ile Gln Gln Ala Gly Asn Ser
 465 470 475 480
 Val Leu Ala Lys Ala Asn Gln Val Pro Gln Gln Val Leu Ser Leu Leu
 485 490 495
 Gln Gly Lys Leu Gly Thr Asn Ala Ala Asn Gln Ala Ala Tyr Gln Lys
 500 505 510
 Ala Leu Ala Ala Tyr Gln Ala Glu Leu Lys Arg Val Gln Glu Ala Asn
 515 520 525
 Ala Ala Ala Lys Ala Ala Tyr Asp Thr Ala Val Ala Ala Asn Asn Ala
 530 535 540
 Lys Asn Thr Glu Ile Ala Ala Ala Asn Glu Glu Ile Arg Lys Arg Asn
 545 550 555 560
 Ala Thr Ala Lys Ala Glu Tyr Glu Thr Lys Leu Ala Gln Tyr Gln Ala
 565 570 575
 Glu Leu Lys Arg Val Gln Glu Ala Asn Ala Ala Asn Glu Ala Asp Tyr
 580 585 590
 Gln Ala Lys Leu Thr Ala Tyr Gln Thr Glu Leu Ala Arg Val Gln Lys
 595 600 605
 Ala Asn Ala Asp Ala Lys Ala Thr Tyr Glu Ala Ala Val Ala Ala Asn
 610 615 620
 Asn Ala Lys Asn Ala Ala Leu Thr Ala Glu Asn Thr Ala Ile Lys Gln
 625 630 635 640
 Arg Asn Glu Asn Ala Lys Ala Thr Tyr Glu Ala Ala Leu Lys Gln Tyr
 645 650 655
 Glu Ala Asp Leu Ala Ala Val Lys Lys Ala Asn Ala Ala Asn Glu Ala
 660 665 670
 Asp Tyr Gln Ala Lys Leu Thr Ala Tyr Gln Thr Glu Leu Ala Arg Val
 675 680 685
 Gln Lys Ala Asn Ala Asp Ala Lys Ala Ala Tyr Glu Ala Ala Val Ala
 690 695 700
 Ala Asn Asn Ala Ala Asn Ala Ala Leu Thr Ala Glu Asn Thr Ala Ile
 705 710 715 720
 Lys Lys Arg Asn Ala Asp Ala Lys Ala Asp Tyr Glu Ala Lys Leu Ala
 725 730 735
 Lys Tyr Gln Ala Asp Leu Ala Lys Tyr Gln Lys Asp Leu Ala Asp Tyr
 740 745 750
 Pro Val Lys Leu Lys Ala Tyr Glu Asp Glu Gln Thr Ser Ile Lys Ala
 755 760 765
 Ala Leu Ala Glu Leu Glu Lys His Lys Asn Glu Asp Gly Asn Leu Thr
 770 775 780
 Glu Pro Ser Ala Gln Asn Leu Val Tyr Asp Leu Glu Pro Asn Ala Asn
 785 790 795 800
 Leu Ser Leu Thr Thr Asp Gly Lys Phe Leu Lys Ala Ser Ala Val Asp
 805 810 815
 Asp Ala Phe Ser Lys Ser Thr Ser Lys Ala Lys Tyr Asp Gln Lys Ile
 820 825 830
 Leu Gln Leu Asp Asp Leu Asp Ile Thr Asn Leu Glu Gln Ser Asn Asp
 835 840 845
 Val Ala Ser Ser Met Glu Leu Tyr Gly Asn Phe Gly Asp Lys Ala Gly

-continued

850			855			860									
Trp	Ser	Thr	Thr	Val	Ser	Asn	Asn	Ser	Gln	Val	Lys	Trp	Gly	Ser	Val
865					870					875					880
Leu	Leu	Glu	Arg	Gly	Gln	Ser	Ala	Thr	Ala	Thr	Tyr	Thr	Asn	Leu	Gln
				885					890						895
Asn	Ser	Tyr	Tyr	Asn	Gly	Lys	Lys	Ile	Ser	Lys	Ile	Val	Tyr	Lys	Tyr
			900					905					910		
Thr	Val	Asp	Pro	Lys	Ser	Lys	Phe	Gln	Gly	Gln	Lys	Val	Trp	Leu	Gly
		915					920					925			
Ile	Phe	Thr	Asp	Pro	Thr	Leu	Gly	Val	Phe	Ala	Ser	Ala	Tyr	Thr	Gly
930						935						940			
Gln	Val	Glu	Lys	Asn	Thr	Ser	Ile	Phe	Ile	Lys	Asn	Glu	Phe	Thr	Phe
945					950						955				960
Tyr	Asp	Glu	Asp	Gly	Lys	Pro	Ile	Asn	Phe	Asp	Asn	Ala	Leu	Leu	Ser
				965					970						975
Val	Ala	Ser	Leu	Asn	Arg	Glu	His	Asn	Ser	Ile	Glu	Met	Ala	Lys	Asp
			980					985						990	
Tyr	Ser	Gly	Lys	Phe	Val	Lys	Ile	Ser	Gly	Ser	Ser	Ile	Gly	Glu	Lys
		995					1000						1005		
Asn	Gly	Met	Ile	Tyr	Ala	Thr	Asp	Thr	Leu	Asn	Phe	Lys	Gln	Gly	
1010						1015						1020			
Glu	Gly	Gly	Ser	Arg	Trp	Thr	Met	Tyr	Lys	Asn	Ser	Gln	Ala	Gly	
1025						1030						1035			
Ser	Gly	Trp	Asp	Ser	Ser	Asp	Ala	Pro	Asn	Ser	Trp	Tyr	Gly	Ala	
1040						1045						1050			
Gly	Ala	Ile	Lys	Met	Ser	Gly	Pro	Asn	Asn	His	Val	Thr	Val	Gly	
1055						1060						1065			
Ala	Thr	Ser	Ala	Thr	Asn	Val	Met	Pro	Val	Ser	Asp	Met	Pro	Val	
1070						1075						1080			
Val	Pro	Gly	Lys	Asp	Asn	Thr	Asp	Gly	Lys	Lys	Pro	Asn	Ile	Trp	
1085						1090						1095			
Tyr	Ser	Leu	Asn	Gly	Lys	Ile	Arg	Ala	Val	Asn	Val	Pro	Lys	Val	
1100						1105						1110			
Thr	Lys	Glu	Lys	Pro	Thr	Pro	Pro	Val	Lys	Pro	Thr	Ala	Pro	Thr	
1115						1120						1125			
Lys	Pro	Thr	Tyr	Glu	Thr	Glu	Lys	Pro	Leu	Lys	Pro	Ala	Pro	Val	
1130						1135						1140			
Ala	Pro	Asn	Tyr	Glu	Lys	Glu	Pro	Thr	Pro	Pro	Thr	Arg	Thr	Pro	
1145						1150						1155			
Asp	Gln	Ala	Glu	Pro	Asn	Lys	Pro	Thr	Pro	Pro	Thr	Tyr	Glu	Thr	
1160						1165						1170			
Glu	Lys	Pro	Leu	Glu	Pro	Ala	Pro	Val	Glu	Pro	Thr	Tyr	Glu	Leu	
1175						1180						1185			
Glu	His	His	His	His	His	His									
1190						1195									

<210> SEQ ID NO 7

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

gcgccatggc acaagtcatt aatacc

-continued

<210> SEQ ID NO 8
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

 <400> SEQUENCE: 8

 aacaagctta ccctgcagca gagacagaac 30

<210> SEQ ID NO 9
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

 <400> SEQUENCE: 9

 tcaaagcttg gaaccaatgc tgccaatc 28

<210> SEQ ID NO 10
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

 <400> SEQUENCE: 10

 acgtctcgag ctcataagtt ggctcaacag 30

<210> SEQ ID NO 11
 <211> LENGTH: 2880
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: KFD2-PAc fusion protein encoding sequence

 <400> SEQUENCE: 11

 atggcacaag tcattaatac caacagcctc tcgctgatca ctcaaaataa tatcaacaag 60
 aaccagtcctg cgtgtctgag ttctatcgag cgtctgtctt ctggcttgcg tattaacagc 120
 gcgaaggatg acgcagcggg tcaggcgatt gctaaccgtt tcacctctaa cattaaggc 180
 ctgactcagg cggcccgtaa cgccaacgac ggtatctcgg ttgcgcagac caccgaaggc 240
 gcgctgtcgg aaatcaacaa caacttacag cgtgtgcgtg aactgacggt acaggccact 300
 accggtacta actctgagtc tgatctgtct tctatccagg acgaaattaa atcccgtctg 360
 gatgaaattg accgcgtatc tggtcagacc cagttcaacg gcgtgaaact gctggcaaaa 420
 aatggctcca tgaaaatcca ggttgccgca aatgataacc agactatcac tatcgatctg 480
 aagcagattg atgctaaaac tcttgccctt gatgctagcg gaaccaatgc tgccaatcaa 540
 gcagcctatc aaaaagccct tgctgcttat caggctgaac tgaaacgtgt tcaggaagct 600
 aatgcagcgg ccaaagccgc ttatgatact gctgtagcag caaataatgc caaaaataca 660
 gaaattgccc ctgccaatga agaaattaga aaacgcaatg caacggccaa agctgaatat 720
 gagactaagt tagctcaata tcaagctgaa ctaaagcgtg ttcaggaagc taatgccgca 780
 aacgaagcag actatcaagc taaattgacc gcctatcaaa cagagcttgc tcgtgttcaa 840
 aaagccaatg cggatgctaa agcagcctat gaagcagctg tagcagcaaa taatgccaaa 900
 aatgcggcac tcacagctga aaatactgca attaagcaac gcaatgagaa tgctaaggcg 960

-continued

```

acttatgaag ctgcactcaa gcaatatgag gccgatttgg cagcggtgaa aaaagctaata 1020
gccgcaaaag aagcagacta tcaagctaaa ttgaccgcct atcaaacaga gctcgcctcgc 1080
gttcaaaaag ccaatgcgga tgctaaagcg gcctatgaag cagctgtagc agcaataat 1140
gccgcaaatg cagcgcctcac agctgaaaat actgcaatta agaagcgcaa tgcggatgct 1200
aaagctgatt acgaagcaaa acttgctaag tatcaagcag atcttgccaa atatcaaaaa 1260
gatttagcag actatccagt taagttaaag gcatacgaag atgaacaaac ttctattaaa 1320
gctgcactgg cagaacttga aaaacataaa aatgaagacg gaaacttaac agaaccatct 1380
gctcaaaatt tggctctatga tcttgagcca aatgcgaact tatctttgac aacagatggg 1440
aagttcctta aggtctctgc tgtggatgat gcttttagca aaagcacttc aaaagcaaaa 1500
tatgacaaaa aaattcttca attagatgat ctagatatca ctaacttaga acaatctaata 1560
gatgttgctt cttctatgga gctttatggg aatthttggtg ataaagctgg ctggtcaacg 1620
acagtaagca ataactcaca ggtaaatgg ggatcggtac ttttagagcg cggtaaaagc 1680
gcaacagcta catacactaa cctgcagaat tcttattaca atggtaaaaa gattttctaaa 1740
attgtctaca agtatacagt ggaccctaag tccaagtttc aaggtcaaaa ggthttggtta 1800
ggatthttta ccgatccaac tttaggtgtt tttgcttctg cttatacagg tcaagttgaa 1860
aaaaacactt ctatthttat taaaaatgaa ttcactttct atgacgaaga tggaaaacca 1920
attaatthtg ataatgcctt tctctcagta gcttctctta accgtgaaca taactctatt 1980
gagatggcta aagattatag tggtaaatth gtcaaaatct ctggttcctc tattggtgaa 2040
aagaatggca tgatttatgc tacagatact cttaacttta aacaggggta aggtggctct 2100
cgctggacta tgtataaaaa tagtcaagct ggttcaggat gggatagttc agatcgcccg 2160
aattcttggt atggagcagg ggtattataa atgtctggtc cgaataacca tgttactgta 2220
ggagcaactt ctgcaacaaa tgtaatgcca gtttctgaca tgctgttgtt tcttggttaag 2280
gacaatactg atggcaaaaa accaaatatt tggattctt taaatggtaa aatccgtgcg 2340
gttaatgttc ctaaaagttac taaggaaaaa cccacacctc cggttaaaac aacagctcca 2400
actaaaccaa cttatgaaac agaaaagcca ttaaaaccgg caccagtagc tccaaattat 2460
gaaaaggagc caacaccgcc gacaaggaca ccggatcaag cagagccaaa caaacccaca 2520
ccgccgacct atgaacaga aaagccggtg gagccagcac ctggtgagcc aacttatgag 2580
acgacggatc cgctgaaagc gctggacgat gctatcgcat ctgtagacaa attccgttct 2640
tccctcggtg cggtgcaaaa ccgtctggat tccgcgggta ccaacctgaa caacaccact 2700
accaacctgt ctgaagcgca gtcccgtatt caggacgccg actatgagc cgaagtgtcc 2760
aatatgtcga aagcgcagat catccagcag gccgtaact ccgtggtggc aaaagctaac 2820
caggtaccgc agcaggttct gtctctgctg cagggctctg agcaccacca ccaccaccac 2880

```

<210> SEQ ID NO 12

<211> LENGTH: 960

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: KFD2-PAC fusion protein

<400> SEQUENCE: 12

```

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Ile Thr Gln Asn
1           5           10           15

```

```

Asn Ile Asn Lys Asn Gln Ser Ala Leu Ser Ser Ser Ile Glu Arg Leu
20           25           30

```

-continued

Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
 35 40 45
 Ala Ile Ala Asn Arg Phe Thr Ser Asn Ile Lys Gly Leu Thr Gln Ala
 50 55 60
 Ala Arg Asn Ala Asn Asp Gly Ile Ser Val Ala Gln Thr Thr Glu Gly
 65 70 75 80
 Ala Leu Ser Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Thr
 85 90 95
 Val Gln Ala Thr Thr Gly Thr Asn Ser Glu Ser Asp Leu Ser Ser Ile
 100 105 110
 Gln Asp Glu Ile Lys Ser Arg Leu Asp Glu Ile Asp Arg Val Ser Gly
 115 120 125
 Gln Thr Gln Phe Asn Gly Val Asn Val Leu Ala Lys Asn Gly Ser Met
 130 135 140
 Lys Ile Gln Val Gly Ala Asn Asp Asn Gln Thr Ile Thr Ile Asp Leu
 145 150 155 160
 Lys Gln Ile Asp Ala Lys Thr Leu Gly Leu Asp Ala Ser Gly Thr Asn
 165 170 175
 Ala Ala Asn Gln Ala Ala Tyr Gln Lys Ala Leu Ala Ala Tyr Gln Ala
 180 185 190
 Glu Leu Lys Arg Val Gln Glu Ala Asn Ala Ala Ala Lys Ala Ala Tyr
 195 200 205
 Asp Thr Ala Val Ala Ala Asn Asn Ala Lys Asn Thr Glu Ile Ala Ala
 210 215 220
 Ala Asn Glu Glu Ile Arg Lys Arg Asn Ala Thr Ala Lys Ala Glu Tyr
 225 230 235 240
 Glu Thr Lys Leu Ala Gln Tyr Gln Ala Glu Leu Lys Arg Val Gln Glu
 245 250 255
 Ala Asn Ala Ala Asn Glu Ala Asp Tyr Gln Ala Lys Leu Thr Ala Tyr
 260 265 270
 Gln Thr Glu Leu Ala Arg Val Gln Lys Ala Asn Ala Asp Ala Lys Ala
 275 280 285
 Thr Tyr Glu Ala Ala Val Ala Ala Asn Asn Ala Lys Asn Ala Ala Leu
 290 295 300
 Thr Ala Glu Asn Thr Ala Ile Lys Gln Arg Asn Glu Asn Ala Lys Ala
 305 310 315 320
 Thr Tyr Glu Ala Ala Leu Lys Gln Tyr Glu Ala Asp Leu Ala Ala Val
 325 330 335
 Lys Lys Ala Asn Ala Ala Asn Glu Ala Asp Tyr Gln Ala Lys Leu Thr
 340 345 350
 Ala Tyr Gln Thr Glu Leu Ala Arg Val Gln Lys Ala Asn Ala Asp Ala
 355 360 365
 Lys Ala Ala Tyr Glu Ala Ala Val Ala Ala Asn Asn Ala Ala Asn Ala
 370 375 380
 Ala Leu Thr Ala Glu Asn Thr Ala Ile Lys Lys Arg Asn Ala Asp Ala
 385 390 395 400
 Lys Ala Asp Tyr Glu Ala Lys Leu Ala Lys Tyr Gln Ala Asp Leu Ala
 405 410 415
 Lys Tyr Gln Lys Asp Leu Ala Asp Tyr Pro Val Lys Leu Lys Ala Tyr
 420 425 430
 Glu Asp Glu Gln Thr Ser Ile Lys Ala Ala Leu Ala Glu Leu Glu Lys
 435 440 445

-continued

His Lys Asn Glu Asp Gly Asn Leu Thr Glu Pro Ser Ala Gln Asn Leu
 450 455 460

Val Tyr Asp Leu Glu Pro Asn Ala Asn Leu Ser Leu Thr Thr Asp Gly
 465 470 475 480

Lys Phe Leu Lys Ala Ser Ala Val Asp Asp Ala Phe Ser Lys Ser Thr
 485 490 495

Ser Lys Ala Lys Tyr Asp Gln Lys Ile Leu Gln Leu Asp Asp Leu Asp
 500 505 510

Ile Thr Asn Leu Glu Gln Ser Asn Asp Val Ala Ser Ser Met Glu Leu
 515 520 525

Tyr Gly Asn Phe Gly Asp Lys Ala Gly Trp Ser Thr Thr Val Ser Asn
 530 535 540

Asn Ser Gln Val Lys Trp Gly Ser Val Leu Leu Glu Arg Gly Gln Ser
 545 550 555 560

Ala Thr Ala Thr Tyr Thr Asn Leu Gln Asn Ser Tyr Tyr Asn Gly Lys
 565 570 575

Lys Ile Ser Lys Ile Val Tyr Lys Tyr Thr Val Asp Pro Lys Ser Lys
 580 585 590

Phe Gln Gly Gln Lys Val Trp Leu Gly Ile Phe Thr Asp Pro Thr Leu
 595 600 605

Gly Val Phe Ala Ser Ala Tyr Thr Gly Gln Val Glu Lys Asn Thr Ser
 610 615 620

Ile Phe Ile Lys Asn Glu Phe Thr Phe Tyr Asp Glu Asp Gly Lys Pro
 625 630 635 640

Ile Asn Phe Asp Asn Ala Leu Leu Ser Val Ala Ser Leu Asn Arg Glu
 645 650 655

His Asn Ser Ile Glu Met Ala Lys Asp Tyr Ser Gly Lys Phe Val Lys
 660 665 670

Ile Ser Gly Ser Ser Ile Gly Glu Lys Asn Gly Met Ile Tyr Ala Thr
 675 680 685

Asp Thr Leu Asn Phe Lys Gln Gly Glu Gly Gly Ser Arg Trp Thr Met
 690 695 700

Tyr Lys Asn Ser Gln Ala Gly Ser Gly Trp Asp Ser Ser Asp Ala Pro
 705 710 715 720

Asn Ser Trp Tyr Gly Ala Gly Ala Ile Lys Met Ser Gly Pro Asn Asn
 725 730 735

His Val Thr Val Gly Ala Thr Ser Ala Thr Asn Val Met Pro Val Ser
 740 745 750

Asp Met Pro Val Val Pro Gly Lys Asp Asn Thr Asp Gly Lys Lys Pro
 755 760 765

Asn Ile Trp Tyr Ser Leu Asn Gly Lys Ile Arg Ala Val Asn Val Pro
 770 775 780

Lys Val Thr Lys Glu Lys Pro Thr Pro Pro Val Lys Pro Thr Ala Pro
 785 790 795 800

Thr Lys Pro Thr Tyr Glu Thr Glu Lys Pro Leu Lys Pro Ala Pro Val
 805 810 815

Ala Pro Asn Tyr Glu Lys Glu Pro Thr Pro Pro Thr Arg Thr Pro Asp
 820 825 830

Gln Ala Glu Pro Asn Lys Pro Thr Pro Pro Thr Tyr Glu Thr Glu Lys
 835 840 845

Pro Leu Glu Pro Ala Pro Val Glu Pro Thr Tyr Glu Thr Thr Asp Pro
 850 855 860

Leu Lys Ala Leu Asp Asp Ala Ile Ala Ser Val Asp Lys Phe Arg Ser

-continued

865	870	875	880
Ser Leu Gly Ala Val Gln Asn Arg Leu Asp Ser Ala Val Thr Asn Leu	885	890	895
Asn Asn Thr Thr Thr Asn Leu Ser Glu Ala Gln Ser Arg Ile Gln Asp	900	905	910
Ala Asp Tyr Ala Thr Glu Val Ser Asn Met Ser Lys Ala Gln Ile Ile	915	920	925
Gln Gln Ala Gly Asn Ser Val Leu Ala Lys Ala Asn Gln Val Pro Gln	930	935	940
Gln Val Leu Ser Leu Leu Gln Gly Leu Glu His His His His His His	945	950	955
			960

<210> SEQ ID NO 13
 <211> LENGTH: 29
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

tatagctagc ggaaccaatg ctgccaatc 29

<210> SEQ ID NO 14
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 14

attaggatcc gtcgtctcat aagttggctc 30

<210> SEQ ID NO 15
 <211> LENGTH: 1497
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 15

atggcacaag tcattaatac caacagcctc tcgctgatca ctcaaaataa tatcaacaag 60
 aaccagtctg cgctgtcgag ttctatcgag cgtctgtctt ctggottgcg tattaacagc 120
 gcgaaggatg acgcagcggg tcaggcgatt gctaaccggt tcacctetaa cattaaggc 180
 ctgactcagg cggcccgtaa cgccaacgac ggtatctccg ttgctgcagac caccgaagge 240
 gcgctgtccg aaatcaacaa caacttacag cgtgtgctg aactgacggt acaggccact 300
 accggtacta actctgagtc tgatctgtct tctatccagg acgaaattaa atcccgtctg 360
 gatgaaattg accgcgtatc tggtcagacc cagttcaacy gcgtgaacgt gctggcaaaa 420
 aatggctcca tgaaaatcca ggttgcgca aatgataacc agactatcac tatcgatctg 480
 aagcagattg atgctaaaac tcttggcctt gatggtttta gcgttaaaaa taacgataca 540
 gttaccacta gtgctccagt aactgetttt ggtgetacca ccacaaacaa tattaactt 600
 actggaatta cctttctac ggaagcagcc actgatactg gcggaactaa cccagettca 660
 attgagggtg tttatactga taatggtaat gattactatg cgaaaatcac cggtggtgat 720
 aacgatggga agtattacgc agtaacagtt gctaatgatg gtacagtgac aatggcgact 780
 ggagcaacgg caaatgcaac tgtaactgat gcaaatacta ctaaagctac aactatcact 840
 tcaggcggta cacctgttca gattgataat actgcagggt ccgcaactgc caaccttgg 900

-continued

```

gctgtagct tagtaaaact gcaggattcc aagggtaatg ataccgatac atatgcgctt   960
aaagatacaa atggcaatct ttacgctgcg gatgtgaatg aaactactgg tgctgtttct   1020
gttaaaaacta ttacctatac tgactcttcc ggtgcccga gttctccaac cgcggtaaaa   1080
ctgggcccag atgatggcaa aacagaagtg gtcgatattg atggtaaaac atacgattct   1140
gccgatttaa atggcggtaa tctgcaaaaca ggtttgactg ctggtggtga ggctctgact   1200
gctgttgcaa atggtaaaac cacggatccg ctgaaagcgc tggacgatgc tatcgcatct   1260
gtagacaaat tccgttcttc cctcggtgcg gtgcaaaacc gtctggattc cgcggttacc   1320
aacctgaaca acaccactac caacctgtct gaagcgcagt cccgtattca ggacgccgac   1380
tatgcccagg aagtgtccaa tatgtcgaaa gcgcagatca tccagcagge cggtaaactcc   1440
gtgttgccaa aagctaacca ggtaccgcag caggttctgt ctctgctgca gggtaaa   1497

```

<210> SEQ ID NO 16

<211> LENGTH: 498

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 16

```

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Ile Thr Gln Asn
 1          5          10          15
Asn Ile Asn Lys Asn Gln Ser Ala Leu Ser Ser Ser Ile Glu Arg Leu
 20          25          30
Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
 35          40          45
Ala Ile Ala Asn Arg Phe Thr Ser Asn Ile Lys Gly Leu Thr Gln Ala
 50          55          60
Ala Arg Asn Ala Asn Asp Gly Ile Ser Val Ala Gln Thr Thr Glu Gly
 65          70          75          80
Ala Leu Ser Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Thr
 85          90          95
Val Gln Ala Thr Thr Gly Thr Asn Ser Glu Ser Asp Leu Ser Ser Ile
 100         105         110
Gln Asp Glu Ile Lys Ser Arg Leu Asp Glu Ile Asp Arg Val Ser Gly
 115         120         125
Gln Thr Gln Phe Asn Gly Val Asn Val Leu Ala Lys Asn Gly Ser Met
 130         135         140
Lys Ile Gln Val Gly Ala Asn Asp Asn Gln Thr Ile Thr Ile Asp Leu
 145         150         155         160
Lys Gln Ile Asp Ala Lys Thr Leu Gly Leu Asp Gly Phe Ser Val Lys
 165         170         175
Asn Asn Asp Thr Val Thr Thr Ser Ala Pro Val Thr Ala Phe Gly Ala
 180         185         190
Thr Thr Thr Asn Asn Ile Lys Leu Thr Gly Ile Thr Leu Ser Thr Glu
 195         200         205
Ala Ala Thr Asp Thr Gly Gly Thr Asn Pro Ala Ser Ile Glu Gly Val
 210         215         220
Tyr Thr Asp Asn Gly Asn Asp Tyr Tyr Ala Lys Ile Thr Gly Gly Asp
 225         230         235         240
Asn Asp Gly Lys Tyr Tyr Ala Val Thr Val Ala Asn Asp Gly Thr Val
 245         250         255
Thr Met Ala Thr Gly Ala Thr Ala Asn Ala Thr Val Thr Asp Ala Asn
 260         265         270

```

-continued

Thr	Thr	Lys	Ala	Thr	Thr	Ile	Thr	Ser	Gly	Gly	Thr	Pro	Val	Gln	Ile
		275					280					285			
Asp	Asn	Thr	Ala	Gly	Ser	Ala	Thr	Ala	Asn	Leu	Gly	Ala	Val	Ser	Leu
	290					295					300				
Val	Lys	Leu	Gln	Asp	Ser	Lys	Gly	Asn	Asp	Thr	Asp	Thr	Tyr	Ala	Leu
305					310					315					320
Lys	Asp	Thr	Asn	Gly	Asn	Leu	Tyr	Ala	Ala	Asp	Val	Asn	Glu	Thr	Thr
				325						330					335
Gly	Ala	Val	Ser	Val	Lys	Thr	Ile	Thr	Tyr	Thr	Asp	Ser	Ser	Gly	Ala
			340					345						350	
Ala	Ser	Ser	Pro	Thr	Ala	Val	Lys	Leu	Gly	Gly	Asp	Asp	Gly	Lys	Thr
			355				360						365		
Glu	Val	Val	Asp	Ile	Asp	Gly	Lys	Thr	Tyr	Asp	Ser	Ala	Asp	Leu	Asn
	370					375					380				
Gly	Gly	Asn	Leu	Gln	Thr	Gly	Leu	Thr	Ala	Gly	Gly	Glu	Ala	Leu	Thr
385					390					395					400
Ala	Val	Ala	Asn	Gly	Lys	Thr	Thr	Asp	Pro	Leu	Lys	Ala	Leu	Asp	Asp
				405					410						415
Ala	Ile	Ala	Ser	Val	Asp	Lys	Phe	Arg	Ser	Ser	Leu	Gly	Ala	Val	Gln
			420					425						430	
Asn	Arg	Leu	Asp	Ser	Ala	Val	Thr	Asn	Leu	Asn	Asn	Thr	Thr	Thr	Asn
		435					440						445		
Leu	Ser	Glu	Ala	Gln	Ser	Arg	Ile	Gln	Asp	Ala	Asp	Tyr	Ala	Thr	Glu
	450					455						460			
Val	Ser	Asn	Met	Ser	Lys	Ala	Gln	Ile	Ile	Gln	Gln	Ala	Gly	Asn	Ser
465					470					475					480
Val	Leu	Ala	Lys	Ala	Asn	Gln	Val	Pro	Gln	Gln	Val	Leu	Ser	Leu	Leu
				485					490						495

Gln Gly

What is claimed is:

1. A vaccine composition for dental caries caused by *S. mutans* infection, comprising:

- a PAC polypeptide encoded by SEQ ID NO 1 or a variant of the PAC polypeptide represented by SEQ ID NO 2;
- a flagellin polypeptide encoded by SEQ ID NO 3 or a variant of the flagellin represented by SEQ ID NO 4, wherein the flagellin polypeptide or flagellin variant contains a deletion in hypervariable domain of flagellin polypeptide; and
- a pharmaceutically acceptable carrier.

2. The vaccine composition of claim 1, wherein the PAC polypeptide or variant is a recombinant polypeptide conjoining at least two dispersed antigenic epitopes together.

3. The vaccine composition of claim 1, wherein the PAC and flagellin polypeptides are expressed as a single recombinant protein.

4. The vaccine composition of claim 3, wherein the single recombinant protein is encoded by SEQ ID NO 6.

5. The vaccine composition of claim 1, wherein the PAC polypeptide is inserted into the hypervariable domain of the flagellin polypeptide or substitutes partial or whole hypervariable domain of the flagellin polypeptide.

6. The vaccine composition of claim 5, wherein the PAC polypeptide is inserted into the hypervariable domain of the flagellin polypeptide to produce a PAC-flagellin polypeptide, and wherein the PAC-flagellin polypeptide is encoded by SEQ ID NO 12.

7. The vaccine composition of claim 1, wherein the PAC and flagellin polypeptides are tagged or conjugated with complementary moieties that bring these two molecules into close proximity.

8. The vaccine composition of claim 1, wherein the PAC and flagellin polypeptides are conjugated together.

9. The vaccine composition of claim 1, wherein the PAC and flagellin polypeptides are bound to a carrier that brings these two molecules into close proximity.

* * * * *